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Abstract
Cytochrome P450 enzymes function to catalyze a wide range of reactions important for various biological
processes. In humans, the CYP3A subfamily is particularly critical for drug response. Within this family
are CYP3A4 and CYP3A5, which collectively metabolize greater than half of all currently prescribed drugs.
These promiscuous enzymes can bind a broad and structurally diverse array of compounds, in turn
leading to an increased risk of their modulation via small molecules. In the case of CYP3A5, which is overexpressed in some cancers, this leads to chemoresistance. Such aberrant expression and corresponding
drug resistance merit a need to selectively target CYP3A5. However, the significant overlap in sequence
and structural identity with CYP3A4 as well as flexible and dynamic binding modes make development of
a selective inhibitor challenging, and no progress has been made thus far. Moreover, the cancer-specific
regulation of CYP3A5 remains unknown, removing the possibility of targeting a factor upstream of its
transcription. While CYP3A4 regulation in liver is well-documented, these regulators don’t control CYP3A5
in extra-hepatic contexts. This warrants further investigation in order to understand the biological basis of
CYP3A5 over-expression in disease models. Here we present discovery of the first isoform-selective
CYP3A5 inhibitor. We used high-throughput technology to identify clobetasol propionate as capable of
selectively inhibiting CYP3A5 enzymatic activity without conferring CYP3A4 inhibition. We further
demonstrate the in vitro ability of the compound using a clinically relevant cell model with CYP3A5
overexpression and CRISPR/Cas9-mediated full genetic deletion. Additionally, we explore the mechanism
of selectivity, employing computational and biophysical techniques to illustrate how subtle active site
differences allow the compound to adopt a tight heme-ligand coordination exclusively in CYP3A5 and
serving as the basis of its selective inhibition.
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ABSTRACT
Cytochrome P450 enzymes function to catalyze a wide range of reactions
important for various biological processes. In humans, the CYP3A subfamily is
particularly critical for drug response. Within this family are CYP3A4 and CYP3A5,
which collectively metabolize greater than half of all currently prescribed drugs. These
promiscuous enzymes can bind a broad and structurally diverse array of compounds, in
turn leading to an increased risk of their modulation via small molecules. In the case of
CYP3A5, which is over-expressed in some cancers, this leads to chemoresistance. Such
aberrant expression and corresponding drug resistance merit a need to selectively target
CYP3A5. However, the significant overlap in sequence and structural identity with
CYP3A4 as well as flexible and dynamic binding modes make development of a
selective inhibitor challenging, and no progress has been made thus far. Moreover, the
cancer-specific regulation of CYP3A5 remains unknown, removing the possibility of
targeting a factor upstream of its transcription. While CYP3A4 regulation in liver is welldocumented, these regulators don’t control CYP3A5 in extra-hepatic contexts. This
warrants further investigation in order to understand the biological basis of CYP3A5
over-expression in disease models.
Here we present discovery of the first isoform-selective CYP3A5 inhibitor. We
used high-throughput technology to identify clobetasol propionate as capable of
selectively inhibiting CYP3A5 enzymatic activity without conferring CYP3A4 inhibition.
We further demonstrate the in vitro ability of the compound using a clinically relevant
cell model with CYP3A5 overexpression and CRISPR/Cas9-mediated full genetic
deletion. Additionally, we explore the mechanism of selectivity, employing
computational and biophysical techniques to illustrate how subtle active site differences
allow the compound to adopt a tight heme-ligand coordination exclusively in CYP3A5
and serving as the basis of its selective inhibition.
In addition to directly targeting CYP3A5 itself, we also uncovered its upstream
transcriptional regulators in the same cancer-specific context. We developed a
computational pipeline capable of taking large and heterogenous expression data from
patient tumors, and outputting co-expression networks. We leveraged the power of our
tool to produce putative transcriptional regulators of a given target and applied it to
CYP3A5. We screened all candidates experimentally and show that, when knocked
down, our top hits completely ablate CYP3A5 expression. Interestingly, we show that a
peptide and enzyme control CYP3A5 mRNA levels more strongly than our top
transcription factor hit. This discovery highlights the utility of our tool and illuminates
previously unreported targets, ultimately providing more insight into the biology of
CYP3A5-expressing cancers.
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CHAPTER 1.

INTRODUCTION*

The CYP3A Family of Drug-Metabolizing Enzymes
The human cytochrome P450 3A (CYP3A) family is part of the broader CYP
superfamily of heme-containing enzymes. The CYP3A enzymes are critical for
metabolizing both endogenous and exogenous compounds, and they have been reported
to metabolize more than half of all currently prescribed drugs.1 Members of the CYP3A
family include CYP3A4, CYP3A5, CYP3A7, and CYP3A43. These enzymes catalyze
various reactions and have exceptionally broad substrate specificity. Because of their
ability to interact with structurally diverse compounds, CYP3A enzymes have a high
capacity for modulation to change drug responses. CYP3A4 and CYP3A5 are the best
characterized members of the family and are reported to be mostly functionally
redundant, but they do exhibit differences in their regulation and mRNA expression, as
we have reviewed previously.2 CYP3A4 is considered the most important drugmetabolizing enzyme in the body and is the most abundant isoform in the liver, whereas
CYP3A5 is the primary source of extra-hepatic CYP3A. CYP3A7 is primarily expressed
in fetal liver. 3,4 CYP3A43 remains poorly characterized but does have clinical
significance stemming from its genetic variation.5,6 CYP3A enzymes display high protein
sequence homology (Figure 1-1), which is the basis of the functional redundancy
assumptions made by many researchers. Although several differences in substrate
specificity or catalytic efficiency have been reported within the CYP3A family,7,8 one of
the most striking differences was recently highlighted by evidence implicating CYP3A5
specifically in the progression of pancreatic ductal adenocarcinoma (PDAC).9 Structural
evidence has been obtained for both CYP3A4 and CYP3A5, enabling investigations of
the subtle differences between their active sites. Detailed here are some of the differences
in the drug metabolism and modulation profiles within the CYP3A family. Clinically
relevant consequences of the differences between these enzymes are discussed, and
structural perspectives are provided to further the understanding of isoform-selective
effects.
Interplay Between CYP3A and Small Molecules
The CYP3A enzymes can interact with a vast array of small molecules.
Accordingly, it’s of no surprise that these molecules are of differing classes, come from
different sources, and have different intended biological functions.

-------------------*Reprinted from final submission with permission. Lolodi, O., Wang, Y. M., Wright, W.
C. & Chen, T. Differential Regulation of CYP3A4 and CYP3A5 and its Implication in
Drug Discovery. Curr Drug Metab 18, 1095-1105,
https://doi.org/10.1016/j.livres.2019.08.001%20 (2017) 2
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Figure 1-1.

Protein sequence homology among CYP3A enzymes.

Members of the human CYP3A family were aligned and colored by protein sequence
homology, with blue indicating a complete match and white indicating a residue
deviation.
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Roles Involving Endogenous Compounds
Most current research involving enzymes of the CYP3A family relates to their
modulation by, or interactions with, exogenous compounds, primarily those intended for
medicinal purposes. However, important and clinically relevant information has been
obtained from studies of the endobiotic roles of these enzymes. Although CYP3A
enzymes act on a wide range of structurally diverse compounds, most studies of these
enzymes in the context of endogenous metabolism have focused on substrates with
structural similarities. For example, CYP3A members play an important role in bile acid
and steroid metabolism. CYP3A4, CYP3A5, and CYP3A7 selectively catalyze the 1βhydroxylation of the secondary bile acid deoxycholic acid.10 The 1β-hydroxydeoxycholic
acid (1β-OHDCA) metabolite has been proposed as a urinary biomarker with which to
assess potential CYP3A-mediated drug–drug interactions.10 Cholesterol, another
endogenous steroid, also has a metabolite produced by CYP3A4 and CYP3A5, which
again demonstrates the clinical relevance of the CYP3A family. Mao et al. reported on
the suitability of the metabolite 4β-hydroxycholesterol (4β-HC) for studying CYP3A
inducers such as the well-established inducer rifampicin.11,12 Knowledge of the CYP3A
inducibility potential contributed by a given drug is key to understanding the response of
that drug. Furthermore, several inducers of CYP3A members act on upstream regulators
and have been implicated in drug-induced liver injury (DILI), as we previously reviewed.
13
Probing for an endogenous metabolite to compare its level to the baseline in the
presence or absence of a drug is one way to detect the CYP3A induction potential of a
compound. Measuring the plasma levels of 4β-HC is a cost-effective and minimally
invasive approach to studying CYP3A4 and CYP3A5.11,14 Measurement of this
metabolite has also been used to compare the inducibility of CYP3A4 with various drugs,
and it has even been applied as a guideline for dosing adjustments.15 The plasma 4β-HC
level has been reported to be a useful parameter for studying CYP3A interactions in
nonhuman animals such as rats, mice, and dogs.16
Although there has been considerable research on deoxycholic acid and
cholesterol metabolism, perhaps the most extensive body of knowledge concerning the
role of the CYP3A family with respect to endogenous steroids has come from
investigations of the sex hormone testosterone. Testosterone has several metabolic fates,
but CYP3A enzymes are responsible for producing the 6β-hydroxy metabolite.17 This
catalysis is widely used to study the effects of potential CYP3A-interacting drugs, owing
to the robustness and sensitivity of regioselective testosterone hydroxylation by these
enzymes. More recently, plasma levels of 4β-hydroxycholesterol have been used for
CYP3A activity probes.18 Assays for measuring the levels of testosterone metabolites by
comparison to those obtained with ketoconazole as a control inhibitor have been
developed and optimized as a straightforward means of assessing CYP3A activity.19
Importantly, CYP3A4 and CYP3A5 have both been shown to catalyze this reaction,
although less metabolite is contributed from CYP3A5 when human liver samples are
used, owing to the lower hepatic expression of CYP3A5.20 Probing for 6βhydroxytestosterone (6β-OHTST) is of particular value when examining samples with
diverse populations of P450s, such as those from liver.21
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Steroidal derivative endogenous substrates of the CYP3A family also exist. One
example was reported by Gupta et al., who demonstrated that CYP3A4 acts upon vitamin
D.22 Although nonselective, CYP3A4 catalyzes the 25-hydroxylation of 1αhydroxyvitamin D2 (1α-OHD2), and, to a lesser extent, 1α-hydroxyvitamin D3 (1αOHD3).22 Before this finding, this 25-hydroxylation was reported as being catalyzed only
by CYP24A1.23 Although 1α-OHD2 can be metabolized by CYP3A4, its capacity to act
as a sensor of CYP3A activity should not be heavily relied upon, as the metabolite
detected in serum does not correlate well with the established 4β-HC metabolite.24
Important Exogenous Substrates and Metabolites
Given the remarkable promiscuity of the CYP3A family, it is not surprising that a
broad range of prescription medications can serve as their substrates. These enzymes can
metabolize many different classes of compound, each comprising many structurally
diverse subsets. The effects of CYP3A–drug interactions vary greatly according to the
individual drug, and these consequences need to be studied carefully to address
unintended side effects. Chemotherapeutics are one class of drug that is largely
implicated in CYP3A interactions.25 For example, the microtubule-destabilizing vinca
alkaloids vincristine, vinblastine, and vindesine are substrates of CYP3A4, CYP3A5, and
CYP3A7.26,27 Other antimitotics of the same parent class, such as the taxanes paclitaxel
and docetaxel, are also metabolized by these enzymes.28,29 Although paclitaxel is subject
to CYP3A-mediated hydroxylation at different sites, it has been demonstrated that the 6α
product is the primary metabolite.30 One consequence of this is a 30-fold loss in the
cytotoxic activity of the drug.30 Likewise, docetaxel is metabolized by CYP3A into
completely inactive metabolites.31 Another example within this subclass is cabazitaxel.
Although this is a substrate for CYP2C8, CYP3A4 is reported to be primarily responsible
for the substantial decrease in the oral bioavailability of the compound.32 CYP3Amediated inactivation of pharmaceuticals is clearly a problem with respect to drug
efficacy; however, some consequences of CYP3A metabolism are more serious and pose
significant health risks to patients via the generation of toxic metabolites.
Tyrosine kinase inhibitors (TKIs) have been adopted as useful compounds for
treating various cancers and other diseases. Many approved drugs within this class are
subject to CYP3A-mediated biotransformation as their primary metabolic pathway, as
reviewed elsewhere.33 Some TKI metabolites not only lessen the intended effects of the
drug, but also exhibit considerable toxicity themselves. Adverse reactions resulting from
these metabolites can lower the quality of life for the patient and often necessitate a
reduction in the dosage of a drug, thus dampening its intended effect.34 The Human
epidermal growth factor receptor/proto-oncogene neu (EGFR/HER-2) inhibitor lapatinib
is one example of a compound whose CYP3A4- and CYP3A5-catalyzed metabolites
have been implicated in severe drug-induced hepatotoxicity and even in some fatalities.35
Furthermore, the concentration of lapatinib can be dramatically influenced by the
induction or inhibition of CYP3A4 activity—260% increases in the AUC have been
reported when the CYP3A4 activity is inhibited with ketoconazole.36 Thus, modulating
the enzymes responsible can influence the concentrations of harmful metabolites.
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Another example of CYP3A-mediated hepatotoxicity arising from TKI metabolism is
associated with the BCR-ABL inhibitor dasatinib. CYP3A4 oxidizes this compound to
produce at least two reactive intermediates with the capacity to covalently bind
proteins.37 Quinone-imine products are formed by further dasatinib oxidation and are
partly responsible for the toxic effects. Interestingly, one of the metabolites is active and
equipotent to dasatinib itself.35 The EGFR inhibitor erlotinib is another approved
medicine of this class that is a substrate of CYP3A4 and CYP3A5.38 Erlotinib is
approved for non–small cell lung cancer and pancreatic cancer, but its toxicity must be
considered before it is given to patients. Skin-related adverse reactions and, more
seriously, acute hepatotoxicity have been reported for this compound.39 Although not
explicitly reported as a function of any one metabolite, it is proposed that this toxicity
occurs via reactive epoxide and electrophilic quinone-imine intermediates produced
largely by CYP3A4.40 Additionally, it is possible that TKI metabolites produced by the
CYP3A pathway induce toxicity by altering gene expression. Microarray profiling has
been used to investigate this effect in patients with PDAC who develop erlotinibassociated skin toxicity, possibly potentiated through CYP3A.41
Outside the realm of chemotherapeutics, opioids are another class of drugs that
are partly metabolized by the CYP3A system. In particular, CYP3A4 has been reported
to be a critical mediator of the efficacy of these compounds and of the patient response to
many of them.42 The use of opioids as pain-management tools for patients with cancer
also requires careful thought regarding the extensive interplay between these drugs and
CYP3A enzymes. The induction or inhibition of opioids by the responsible CYPs may
drastically alter the intended analgesic effects. Administering compounds that result in
CYP3A4 induction, for example, will markedly reduce the pain-alleviating effects and
potentially require higher dosing than would otherwise be expected.42 One commonly
prescribed opioid substrate of CYP3A enzymes is alfentanil, a synthetic opioid that is
metabolized by CYP3A4 and CYP3A5 into the primary metabolite noralfentanil.43
Because of the extensive CYP3A-mediated metabolism of alfentanil, as with several
other opioids, modulation of one of the enzymes responsible can produce drastic effects
in the context of drug disposition. Indeed, it was reported that the induction of CYP3A4
with rifampicin produced a 3-fold increase in alfentanil clearance.44 In addition to small
molecule modulation, inherent expression differences among CYP3A enzymes resulting
from interindividual variability also contribute to this highly variable drug clearance.44
CYP3A Modulation by Small Molecules
The clinical impact of modulating CYP3A enzymes is so significant that the Food
and Drug Administration (FDA) recommends testing new drugs for potential CYP3A
interactions and doing so by using two structurally unrelated substrates.45 Moreover, the
CYP3A family can be modulated by various compounds, including FDA-approved drugs,
in some fashion – with both overlapping and distinct catalytic activities (Figure 1-2).
Among the most potent and effective modulators of CYP3A4 and CYP3A5 are azolecontaining antifungal compounds. Ketoconazole, a prototypical CYP3A inhibitor, has
submicromolar IC50 values for CYP3A4.46
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Figure 1-2.

Effects of various compounds on CYP3A.

Several relevant endogenous compounds, pharmaceuticals, or tool compounds are
indicated as substrates (gray curved arrows), inhibitors (orange flattened arrows),
enzymatic activators (green double arrows), or inducers (purple arrow) of CYP3A.
Known selectivity information is indicated along the circle as red (CYP3A5-selective),
blue (CYP3A4-selective), yellow (CYP3A7-selective), or black (unknown or nonselective).
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Concordantly, ketoconazole mediated CYP3A inhibition in patients dramatically
reduces the metabolism of many drugs that are subject to hepatic clearance. The
inhibitory effects of ketoconazole on CYP3A activity in patient populations have farreaching consequences for drugs intended for various uses, such as diminishing
metabolism of the antipsychotic risperidone,47 the sedative midazolam,48 the kinase
inhibitors fostamatinib49 and midostaurin,50 and the contraceptive drospirenone,51 among
others. The antifungal isavuconazole is a more moderate inhibitor of CYP3A4 than is
ketoconazole, but it still influences the metabolism of CYP3A substrates such as
midazolam and norethindrone in patients.52 Apart from the studies of antifungal effects in
humans, several cell-based in vitro studies have also demonstrated the ability of these
compounds to modulate CYP3A activity and have addressed the responses to specific
isoforms by using recombinantly expressed enzymes. For example, Godamudunage et al.
tested 13 different azole-containing drugs to evaluate their modulation of CYP3A4 versus
CYP3A7.53 Although some of the tested compounds demonstrated CYP3A7 inhibition,
the inhibitory effect of these compounds on CYP3A4 was consistently more
pronounced.53 This is of particular clinical relevance because CYP3A4 is expressed in
adult liver, whereas CYP3A7 is primarily expressed in neonates. Moreover, when testing
nine antifungals for CYP3A4 and CYP3A5 inhibition, Niwa et al. reported that the
commonly prescribed itraconazole, ketoconazole, and miconazole were more inhibitory
than were other azole drugs.54
Antiretroviral drugs are an example of a class of compounds that contains both
inducers and inhibitors of CYP3A. Some drugs in this class can directly bind to and
inactivate CYP3A enzymes, whereas others interact with upstream transcription factors
and induce CYP3A expression. CYP3A4 for example is inducible primarily via the
Pregnane X Receptor (PXR), but also by other nuclear receptors like the Constitutive
Androstane Receptor (CAR), Retinoid X Receptor (RXR), Vitamin D Receptor (VDR),
and transcription factors like Hepatocyte Nuclear Factor 4 alpha (HNF4A).55,56 Various
antiretrovirals induce CYP3A4 by engaging its upstream regulators. For example,
efavirenz is an antiretroviral that strongly induces the expression of CYP3A4 via
activation of the human transcription factor pregnane X receptor (PXR),54 whereas
atazanavir inhibits CYP3A4.57 Ritonavir is one of the strongest CYP3A inhibitors in this
class, having an IC50 of 14 nanomolar, and is even used as a pharmacokinetic boosting
agent for other similar compounds because it so effectively halts CYP3A catalysis.58
Interestingly, the strong inhibitory effect of this antiretroviral can be exploited for other
drug classes. For example, it has been proposed to use ritonavir in patients with cystic
fibrosis (CF) to inhibit the metabolism of the anti-CF drug ivacaftor and thereby curtail
the CYP3A-mediated adverse effects that would otherwise result in reduced efficacy of
the latter drug.59 Cobicistat is often used in a similar manner to ritonavir and acts as an
inhibitor for and substrate of CYP3A4.60 Although both of these drugs modulate CYP3A
via potent inhibition, cobicistat has been reported to be more specific for CYP3A, having
fewer interactions with other CYPs;61 accordingly, it has been proposed as an important
component of combination regimens for Human immunodeficiency virus (HIV)
management.62 Not all antiretroviral drugs modulate CYP3A enzymes equipotently,
however: Although ritonavir is a preferential and potent inhibitor of CYP3A4 and
CYP3A5, its inhibition of CYP3A7 is weaker.63 This information may prove beneficial
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when treating infants with these compounds. The varying effects and wide potential for
CYP3A-mediated adverse interactions when antiretrovirals are used in combination with
other medications necessitates careful consideration when prescribing these drugs.
Apart from conventional medications that act as small molecule modulators of
CYP3A, natural products present in common foods can also exert such effects. The bestknown example was discovered nearly 30 years ago when it was reported that grapefruit
juice changed the bioavailability of the antihypertensives felodipine and nifedipine.64 It is
now accepted that more than 80 commonly prescribed drugs interact unfavorably with
grapefruit juice, resulting in serious adverse reactions such as rhabdomyolysis,
myelotoxicity, nephrotoxicity, and respiratory depression.65 The observed consequences
are a direct result of potent inhibition of CYP3A enzymes (primarily CYP3A4, according
to reports), which results in a failure to metabolize these compounds and, thus, in the
accumulation of toxic concentrations in the body. Bergamottin is the furanocoumarin in
grapefruit that is responsible for CYP3A4 inhibition; importantly, it causes mechanismbased (or “suicide”) inactivation.66 This irreversible inhibition is caused by covalent
modification of CYP3A4 and contributes more substantially to a reduction in the
available enzyme when compared to a reversible inhibitor.67 In addition to the
unfavorable increase in the bioavailability of many drugs, grapefruit juice also inhibits
the metabolic activation of CYP3A prodrugs—two examples thus affected are the blood
thinners clopidogrel and prasugrel.68,69 Other natural products originating from fruits and
vegetables have been reported as modulators of CYP3A enzymes. Cabbage and onion
juices, for example, were reported to be inhibitors of CYP3A4 activity in both
biochemical- and cell-based experiments.70 Bael fruit,71 evodia fruit,70 goji berry,72 and
starfruit73 all contain small molecule CYP3A inhibitors that lead to various adverse drug
interactions. Studies have also implicated CYP3A enzymes in herb-drug interactions.
These studies help to explain some of the toxicities associated with traditional medicines
and modern drugs. Cat’s claw and peppermint oil are examples of highly potent CYP3A4
inhibitors that may interfere with prescription medications.74 Schisandra chinensis
(magnolia vine) is a plant used in traditional Chinese medicine that contains CYP3A4
and CYP3A5 inhibitors that lead to dramatically higher bioavailability profiles of certain
CYP3A-interacting drugs.75 Furthermore, natural products from foods and herbs can also
be inducers of CYP3A enzymes. St. John’s wort is one such example; hyperforin, a
component of St. John’s wort, acts as a potent inducer of CYP3A4 expression by
activating its upstream transcriptional regulator PXR.76,77 The use of this herb in patients
taking prescription medications presents a serious safety concern because of the high
potential for interactions.78 The routine consumption of food products containing CYP3A
modulators may account for observed differences in drug efficacy and toxicity, beyond
what can be explained by interindividual variability.
One interesting form of CYP3A modulation is that of direct enzymatic activation,
whereby a compound binds to an enzyme and induces a level of enzymatic activity that is
higher than the basal levels. Modulators in this category are generally considered to be
allosteric regulators that bind outside or distal from the classical heme-containing active
site in a manner that structurally enables increased catalysis. A few researchers have
hypothesized the existence of peripheral ligand-binding sites for CYP3A4.79–80 The
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compound 5-(4-fluorobenzyl)-2-((3-fluorophenoxy)methyl)-4,5,6,7tetrahydropyrazolo[1,5-a]pyrazine (hereafter referred to as VU0448187) is an activator of
CYP3A4 and CYP3A5 that increases midazolam hydroxylation activity by more than
100-fold compared to the baseline level.81 Interestingly, the activity of VU0448187 is
reportedly substrate dependent; it affects the hydroxylation of midazolam, but not that of
testosterone and progesterone. 82 As VU0448187 is intended as a ligand of metabotropic
glutamate receptor 5 (mGlu5), there is a possibility of drug–drug interactions.81 Similarly,
the prescription androgen receptor antagonist flutamide and its metabolite 2hydroxyflutamide are also CYP3A heterotropic activators.83 Flutamide can induce
CYP3A4 and CYP3A5 midazolam hydroxylation activity that is more than 100% higher
than the basal level and can result in a dramatic increase in the CYP3A substrates
nifedipine and amiodarone.83 A particularly interesting case of CYP3A activation
involves the platelet aggregation inhibitor ticagrelor. This compound exhibits an
intriguing bimodal modulation of CYP3A activity, whereby the hydroxylation of
midazolam to 4-hydroxymidazolam is mildly inhibited but the conversion to 1hydroxymidazolam is mildly increased.84 This may contribute to the adverse effects seen
when patients are given ticagrelor with CYP3A inducers.82 Progesterone has also been
proposed as a CYP3A4 allosteric activator,85 but little work has been done to investigate
its effect on drug–drug interactions as a direct result. Isoform-selective allosteric
activation was reported with the TKI icotinib, which appears to activate CYP3A5 but not
CYP3A4.86 Small molecule enzymatic activators of CYP3A family members represent
yet another potential source of drug–drug interactions. The unintended increase in
CYP3A metabolic activity (and, thus, the unintended increase in CYP3A-mediated
metabolism of drugs) means that caution is warranted when drugs are taken alongside
these activators.
Selective Catalysis and Substrate Recognition
Members of the CYP3A family are commonly regarded as having enough
overlapping substrate specificity to justify considering them as a single enzyme. Indeed,
many research studies do not differentiate between the isoforms and frequently use
annotations such as “CYP3A4/5.” The tissue-specific expression and overall abundance
of each enzyme in the CYP3A family is occasionally taken into account, but the
individual metabolic capabilities of these enzymes receive much less consideration.
However, several isoform-specific or isoform-preferential reactions are known to occur
within the CYP3A family, and some have clinical relevance. In recent years, important
tool compounds have been developed that exploit subtle differences between CYP3A4
and CYP3A5, enabling evidence of isoform-specific catalytic activities to be obtained. In
2012, two separate groups published the first reports of CYP3A4-selective inhibitors. SR9186 is a CYP3A4 inhibitor demonstrating 1000-fold selectivity over CYP3A5,87
whereas CYP3cide is a mechanism-based (irreversible) CYP3A4-selective inhibitor.88 At
present, there is no selective CYP3A5 inhibitor available. Although there is a clear need
for an isoform-selective CYP3A5 inhibitor, it has been suggested that the development of
such a compound presents a considerable challenge. 9,89,90 This is probably based on the
observation that when a compound tends to inhibit both CYP3A4 and CYP3A5, it is
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almost always CYP3A4 that is more potently inhibited. However, a probe compound for
selectively measuring CYP3A5 does exist. In 2014, the N-oxide metabolite of the
phosphodiesterase inhibitor T-1032 (hereafter referred to as T5NO) was the first
compound to be identified as a highly selective metabolite catalyzed by CYP3A5,
demonstrating greater than 100-fold selectivity over CYP3A4.91 Although T-1032 is
metabolized by CYP3A4, CYP3A5, and CYP2C8, the T5NO metabolite is produced
almost exclusively by CYP3A5. These tool compounds have proved instrumental in the
delineation of the discrete contributions of CYP3A isoforms.
Vincristine was one of the earliest compounds reported to be catalyzed
preferentially by a CYP3A isoform. Dennison et al.7 tested various recombinantly
expressed CYPs and showed that vincristine oxidation was significantly more efficient in
the context of CYP3A5 as compared to CYP3A4. In a subsequent study, the same authors
further characterized the CYP3A5-mediated 14-fold metabolite increase, reporting that
genetic polymorphisms of CYP3A5 play major roles in the biotransformation of this
compound.92 Moreover, when CYP3A5 is inactive because of genetic polymorphisms,
vincristine-induced toxicity is heightened, further suggesting that CYP3A5 is critical for
the clearance of this drug.93 Importantly, there is evidence that the CYP3A5 genotype is
not the only causative factor associated with vincristine toxicity.94 No structure for
CYP3A5 bound with vincristine has yet been solved, but molecular dynamics simulations
have been employed to help explain its preferential catalysis,95 and the researchers who
conducted those simulations hypothesized that vincristine binds to CYP3A5 in an
orientation different from that of CYP3A4, enabling it to interact more tightly with
critical active-site residues. Another well-characterized association between CYP3A5 and
selective catalysis is that observed with the immunosuppressant tacrolimus. Patients
receiving organ transplants are prescribed this drug to suppress their immune systems to
avoid rejection of the transplant. Both CYP3A4 and CYP3A5 can metabolize tacrolimus
into 13-O-tacrolimus, but the catalytic efficiency is 64% higher for CYP3A5.96 As with
vincristine, genetic polymorphisms of CYP3A5 (particular those that classify patients as
“expressors” versus “non-expressors”) contribute dramatically to the efficacy of the drug
and provide the basis for dosing adjustments.97 Because tacrolimus is one of the few
drugs that is catalyzed preferentially by CYP3A5, the expression levels of the functional
CYP3A5 isoform of a patient must be carefully considered when prescribing this drug.
Naturally, nonselective inhibition of CYP3A5 via ketoconazole or cyclosporine A also
affects tacrolimus biotransformation and, thus, the proper dosage.8
When panels of compounds are tested for their CYP3A4 and CYP3A5 inhibitory
potential, the general pattern is that if a compound inhibits CYP3A4 then it probably also
inhibits CYP3A5.98 Similarly, most substrates of CYP3A4 are also substrates of
CYP3A5. Although the potencies usually differ (with most compounds being more potent
for or more efficiently catalyzed by CYP3A4 than CYP3A5), changes greater than 2- to
5-fold are not commonly observed. Because CYP3A4 is the primary CYP3A enzyme
expressed in liver, side-by-side comparisons with CYP3A5, using recombinantly
expressed enzymes, have been only infrequently conducted. However, one CYP3A4selective compound was reported in 2016, when it was demonstrated that gomisin A is
metabolized nearly 13 times more efficiently by CYP3A4 than by CYP3A5.99 CYP3A4

10

preferentially catalyzes the hydroxylation of this natural compound to 8-hydroxygomisin
A, and this product was not detected when other human CYPs were tested. Interestingly,
gomisin A is also reported to be an inhibitor of CYP3A4.100 Compounds serving as
substrates that are also inhibitors at clinically relevant concentrations may help to provide
insights into modes of isoform-selective catalysis and/or inhibition of the human CYP3A
family. Moreover, gomisin A is of additional interest because of its hepatoprotective
effects, which may be directly related to interplay with CYP3A4.101,102 Another important
example of a compound that is selectively catalyzed by CYP3A4 is luciferin-IPA, which
has been developed by Promega for use in drug-development assays.103 This is a “proluciferin” that is selectively metabolized into D-luciferin by CYP3A4, with very minimal
cross-reactivity from other CYP3A members and none from various other human
CYPs.103 Adding luciferase to the system yields a luminescent signal, and this technique
has been routinely used as a robust measure of various biological processes, such as
cytotoxicity.104 Leveraging this in the context of CYP3A, the signal from luciferin-IPA
being converted to D-luciferin (and ultimately luminescence) is directly proportional to
the CYP3A4 activity, making this method suitable for high-throughput drug-development
screens.105 In systems that express multiple CYP3A family members, isoform-selective
substrates such as these are important tools for uncovering the individual roles of a given
isozyme.
Structural Insights
With the recent progress in crystallization of CYP3A5, new insights have been
gained into the slight differences between CYP3A4. Such nuances in secondary
structures provide details into discrete modes of binding and catalysis.
Secondary Structures and Flexibility
Several crystal structures of human CYP3A4 have been solved and deposited in
the Protein Data Bank (PDB, https://www.rcsb.org). These structures serve as
informative tools with which to further the understanding of the enzymatic function of
this molecule. The flexibility of CYP3A4 has been well established and is an essential
part of its ability to so promiscuously recognize and bind compounds.106 The ligandaccessible volume of the CYP3A4 binding pocket is estimated to be very large at 520
Å3.107 It can bind a greatly diverse set of ligands (i.e., compounds that bind to the
CYP3A4 binding pocket) and even exhibits multiple conformations itself.108 CYP3A4
and CYP3A5 have been described as having the highest catalytic promiscuity among the
major human CYPs.109 Some of the structural diversity of the compounds that bind to
CYP3A4 can be observed in the various crystal structures. Although structurally diverse,
these ligands also have varying functions. Compounds that exemplify the structural and
functional diversity of CYP3A4-binding ligands, as determined using x-ray
crystallography, include the endogenous hormone progesterone,110 the antibiotic
erythromycin,111 the antifungal ketoconazole,111 the antiretroviral ritonavir,112 the
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dopamine promoter bromoergocryptine,109 and the sedative midazolam (Figure 1-3).113
Interestingly, the cavity can adapt to accommodate multiple ligands at once, as seen with
ketoconazole and ritonavir. It can also adopt a conformation that may present a
noncanonical binding site (as seen with progesterone). The most striking differences in
flexibility when binding various ligands occur in the F–F′ region.114 This change is
apparent when the ligand-free states of CYP3A4 (in the absence of ligand or coordinated
to a water molecule) are compared with the structure that has two molecules of
ketoconazole bound and an expanded active site (Figure 1-4). 111, 115-116 The F–F′ region
is expanded outward as a result of the inherent flexibility of the secondary structure lining
the roof of the pocket. This culminates in an expanded state that can accommodate two
molecules of ketoconazole. The ability of CYP3A4 to conform to diverse molecules is a
direct function of this secondary structure flexibility.
Only one crystal structure has been solved for CYP3A5. In 2018, Hsu et al. were
the first to crystalize CYP3A5, bound with the potent inhibitor ritonavir. 117 This was the
first concrete evidence that although CYP3A4 and CYP3A5 have largely homologous
overall secondary structures, certain residues lining the binding pocket of CYP3A5 do
indeed confer a unique shape. Amino acid residues in the F–F′ region are positioned
slightly differently in the two enzymes. Consequently, the CYP3A4 binding pocket has a
comparatively shorter and more horizontal shape when compared to the CYP3A5 binding
pocket, whereas the roof of the latter pocket is higher and narrower than that of the
CYP3A4 pocket.117 Subtle changes such as these probably contribute to the differences
that constitute the basis for isoform-selective inhibition and catalysis, where observed.
On comparing the CYP3A5 structure to CYP3A4 crystallized with the same ligand,118 it
is apparent that ritonavir can extend into the roof of the CYP3A5 binding pocket but is
blocked by the position of F213 in CYP3A4 (Figure 1-4b). It is, therefore, reasonable to
suppose that compounds that extend into this available region of CYP3A5 could be
developed as selective substrates or inhibitors. This structure presents an opportunity to
exploit key differences between these two enzymes to further understand their selectivity.
Contrasting Active Sites and Consequences Therein
The in-depth exploration of active-site differences of CYP3A enzymes and the
resulting biological consequences is just beginning. At present, no crystal structure exists
for CYP3A7 or CYP3A43. However, kinetic analyses and in silico studies can provide
insights into the selectivity of these enzymes and other CYP3A family members. It was
previously reported that these enzymes exhibit regioselective and stereoselective
differences in testosterone metabolism.119 It is well established that CYP3A family
members are responsible for testosterone metabolism.17 Interestingly, however, Kandel et
al. investigated the apparent differences in the production of 6β-hydroxytestosterone (6βOHT), 2α-hydroxytestosterone (2α-OHT), and 2β-hydroxytestosterone (2β-OHT) and
proposed that active-site differences between CYP3A4/5 and CYP3A7 contribute to
testosterone binding in a position that favors the 2α-OHT metabolite.120 The differences
in the binding mode and resulting metabolite suggest that the 2α-OHT product is
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Figure 1-3.

Promiscuity of the CYP3A ligand binding pocket.

The crystal structures of CYP3A4 were obtained from PDB and aligned to illustrate the
structural diversity of ligands capable of binding to CYP3A4. Progesterone (PDB :
5A1P) is shown in light green, Eerythromycin (PDB: 2J0D) in orange, Kketoconazole
(PDB : 2V0M) in blue, Rritonavir analog (PDB : 4K9U) in pink, Bbromoergocryptine
(PDB: 3UA1) in yellow, and Mmidazolam (PDB : 5TE8) in green. Asterisks (*) indicates
that two molecules of the same ligand are bound in the respective structures.
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Figure 1-4.

Structural differences in CYP3A conformations.

(A) CYP3A4 demonstrates flexibility in the active site. Ketoconazole-bound (PDB :
2V0M) (blue), water-bound (PDB : 4I3Q) (purple), or ligand-free (PDB : 1TQN) (gray)
structures of CYP3A4 are overlaid. The flexibility of the F–F′ region at the roof of the
binding pocket in the ketoconazole-bound structure is indicated by the yellow arrow. (B)
Differences in key active-site residues in CYP3A4 and CYP3A5 contribute to the
differential binding modes of ritonavir. Ritonavir-bound CYP3A4 (PDB : 3NXU) (blue)
superimposed with ritonavir-bound CYP3A5 (PDB : 5VEU) (raspberry) demonstrates
slightly different ligand-binding poses. The magnified panel shows the residues
responsible for this difference in CYP3A4 (cyan) versus CYP3A5 (red).
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important in the fetal environment, as CYP3A7 is the primary fetal CYP3A enzyme. This
could also serve as an example of how subtle differences between CYP3A catalytic sites
confer different and potentially biologically relevant activities. Another example of
differential effects among CYP3A enzymes that result from differences in their active
sites is seen with the lignan compounds gomisin C and gomisin G.75 The inhibition
profiles of these compounds appear to be different for CYP3A4 versus CYP3A5, with
consequent varying effects on the substrates midazolam, testosterone, and nifedipine.
This is intriguing because gomisin C and gomisin G share high structural similarity and
have the same molecular weight. When in silico modelling studies were performed,
docking of these compounds revealed an interesting CYP3A5-exclusive hydrogenbonding interaction.75 Importantly, these compounds also showed different capacities for
interaction with heme groups. It is plausible that the minor differences between CYP3A
active sites, which were previously considered trivial, are responsible for how certain
molecules fit and interact differently within these enzymes and, thus, elicit differing
biological consequences.
Comparisons to Other Human CYPs
Although the CYP3A family comprises the CYPs that metabolize the widest
range of compounds, other enzymes in this superfamily also play critical roles in drug
metabolism and response to stimuli. Humans have 18 distinct CYP families, and it is
accepted that the most abundant and biologically relevant members hail from CYP1,
CYP2, CYP3, and CYP4.120 These families do share some redundancy, but specific roles
in metabolism and disease progression have been reported for various enzymes within
them. Moreover, differences in their tissue-specific expression patterns have provided
clues to their intended functions and clinical relevance. The CYP1 family is one of the
primary CYP families expressed in lung.121 Interestingly, CYP3A5—but not CYP3A4—
is expressed in lung with the CYP1 family.121 Within the CYP1 family, CYP1A1,
CYP1A2, and CYP1B2 catalyze the activation of polycyclic aromatic hydrocarbons,122
and they have recently been reported to possess pro-cancer effects.123 The inhibition of
CYP1B1 has recently been reported to have anti-angiogenic activities, and it has been
suggested to be an important target for anticancer strategies.123,124 Unlike the CYP3A
family, which is transcriptionally regulated by PXR, CYP1 is controlled the aryl
hydrocarbon receptor (AHR).125 The CYP2 family includes some of the primary CYPs
expressed in endothelium, myocardium, and kidney,126 but members can be found in
other tissues too. CYP2B6 is among the most clinically relevant CYP2 enzymes; it is
proposed to metabolize around 2% to 10% of clinically prescribed drugs.127 CYP2B6 is
the primary CYP inhibited by drugs such as artemisinin, bupropion, cyclophosphamide,
and ketamine.128 The constitutive androstane receptor (CAR), which is known to have
overlapped regulation and function with PXR, transcriptionally controls the expression
of this enzyme. Like the members of the CYP3A family, CYP2B6 is highly polymorphic
and displays population disparities in its genotype.128 The CYP4 family comprises 13
members that are primarily implicated in the metabolism of eicosanoids and fatty acids,
most notably through their ω-hydroxylase activity.129 This family has been specifically
implicated in the progression of fatty acid–linked diseases and certain cancers, and its
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members represent an important class of drug targets.130 Like all CYPs, these enzymes
have a heme group that is important for catalytic activity. However, CYP4 enzymes
generally prefer to covalently bind their heme group, whereas the CYP3A enzymes
catalyze a reaction and turn over the product, leaving them ready to repeat the process.131
CYP4F2 and CYP4F12 are expressed in liver and are currently being investigated as
biomarkers for hepatocellular carcinoma.132
Further Perspectives
It is clear that CYP3A enzymes are critical for endogenous metabolism,
xenobiotic response, the mediation of drug–drug interactions, and other important
biological processes. Less clear however, has been the discrete role that a given enzyme
in this family might play and whether that role was of any biological importance. The
recent efforts to delineate isoform-selective roles of CYP3A enzymes have shown that
interesting and clinically relevant functions exist within the vast overlap. CYP3A
enzymes are affected in different ways by various compounds, ranging from endogenous
metabolites used as biomarkers to inducers that weaken intended drug effects. Comparing
these enzymes in the context of structure, expression, substrate recognition, activity
modulation, and catalytic efficiency has yielded insights into the most important
differences. It has now been shown that the active sites of CYP3A4 and CYP3A5 have
different shapes. It is likely that many compounds can be recognized by both isoforms
because their active sites can usually conform to fit the various shapes. However, certain
compounds demonstrate that there are scenarios in which compounds bind and confer
either preferential catalysis or (in the case of CYP3A4) selective inhibition. These
compounds appear to exploit key differences to elicit the observed selectivity. The
identification of isoform-selective inhibitors of CYP3A4 suggests that it might also be
possible to selectively inhibit CYP3A5, although given the generally higher inhibition
potential of CYP3A4, this is likely to be a challenge. Nevertheless, examples such as
vincristine and tacrolimus prove that at least some small molecules can be metabolized
preferentially by CYP3A5, which is good news in the context of developing a selective
CYP3A5 inhibitor. The preferential catalysis of 2α-hydroxytestosterone by CYP3A7
suggests that the latter enzyme may play important roles in development and perhaps
even in disease progression. The distinct functions and drug-interaction profiles of
CYP3A4, CYP3A5, and CYP3A7 warrant a further characterization of the metabolic
capability of CYP3A43, which has been little studied so far. Furthermore, and beyond the
scope of this review, genetic polymorphisms within the CYP3A family may represent an
extra layer of regulation by changing the substrate recognition or inhibition potential of
these enzymes. Elaboration on what has been reported so far regarding CYP3A
selectivity is warranted to obtain a more complete understanding of the biological
contributions of each enzyme and how they can be exploited in medicine
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Hypothesis and Specific Aims
Differential expression and tissue distribution of CYP3A4 and CYP3A5 suggest
that these enzymes may have discrete functions, particularly in disease, and thereby have
the potential to be differentially modulated by small molecules. While these homologs
share a breadth of substrates encompassing large and structurally diverse chemical
matter, progress in selective CYP3A4 inhibition and identification of a few CYP3A5selective substrates suggests that small molecule isoform-selective inhibition of CYP3A5
may be possible. Furthermore, the selective over-expression of CYP3A5 in certain
cancers points to a distinct regulatory system of transcriptional control independent of
CYP3A4 regulators.
We hypothesize that CYP3A5 catalytic activity can be chemically inhibited using
a small molecule which does not inhibit CYP3A4 activity. We further hypothesize that
CYP3A5 is under transcriptional regulation in cancer by factors independent of CYP3A4
regulation, and this presents another point by which CYP3A5 can be targeted. To validate
our hypothesis, we propose the following specific aims:
Aim 1: Small Molecule Selective Inhibition of CYP3A5
To use high-throughput screening with an appropriate biochemical assay to test
compounds for selective CYP3A5 inhibition, and to further validate the inhibition
potential in cell-based systems.
Aim 2: Characterizing Mechanism of Isoform-Selective Inhibition
To make use of computational and biophysical techniques to understand the basis
of selectivity between CYP3A4 and CYP3A5, detailing the small molecule-mediated
discrimination of their catalytic activities.
Aim 3: Uncovering Transcriptional Regulators of CYP3A5 in Cancer
To develop a novel method for predicting putative transcriptional regulators of
CYP3A5, and to test them by measuring CYP3A5 mRNA levels upon their RNAimediated knockdown.
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CHAPTER 2.

SELECTIVE INHIBITION OF CYP3A5*

Relevance of Selective Modulation
The cytochrome P450 (CYP) superfamily of heme-containing enzymes is
responsible for catalyzing a wide range of biological processes. The heme group is
critical for the catalytic activity of CYPs, with a highly reactive heme iron-oxo species
(compound I) being responsible for the oxidation of CYP substrates bound close to the
heme iron133,134. The 3A subfamily of CYPs (CYP3A) is critical for xenobiotic clearance
in humans and is reported to metabolize more than half of all currently prescribed
drugs135,136. Although the members of this family include CYP3A4, CYP3A5, CYP3A7,
and CYP3A43, it is CYP3A4 and CYP3A5 that are the primary CYP enzymes expressed
in adults137,138. These enzymes are promiscuous and have exceptionally broad substrate
specificity. They metabolize various pharmaceuticals, natural products, and endogenous
small molecules. This is possible, in part, because of their ability to bind diverse,
structurally unrelated compounds within their large active sites (as we recently
reviewed139). Such indiscriminate binding is the basis for many compounds being able to
modulate CYP3A, thereby decreasing drug efficacy or drug–drug interactions140-143.
Ligand promiscuity of CYP3A4 and CYP3A5 homologs is one reason why these
enzymes are considered functionally redundant120. Compared to CYP3A5, CYP3A4 is
more predominantly expressed in the normal liver, the primary site of drug metabolism,
which explains why CYP3A4 is regarded as the representative member of the CYP3A
family137. Furthermore, the US Food and Drug Administration (FDA) recommends
testing potential pharmaceuticals for CYP3A inhibition and does not differentiate
between CYP3A4 and CYP3A5144,145. For these reasons, the enzymes are ubiquitously
grouped together as “CYP3A4/5” in most expression- and metabolism-related studies.146150
However, emerging evidence suggests that these isozymes are not as redundant as
previously thought.
CYP3A5 is reportedly overexpressed in pancreatic ductal adenocarcinoma
(PDAC) and mediates chemoresistance in different subtypes of this cancer9. Importantly,
RNA interference (RNAi)-mediated knockdown of CYP3A5 re-sensitizes the drugresistant PDAC cells, confirming the role of elevated CYP3A5 levels in drug resistance9.
Although this is the first evidence that selectively inhibiting CYP3A5 might be clinically
significant, previous reports have discussed the need for a CYP3A5-selective inhibitor as
a tool compound with which to differentiate CYP3A5 from CYP3A490. The challenge of
finding such a tool compound is intensified by CYP3A4 being generally more
catalytically active, although this property aided the development of CYP3A4-selective
-------------------*Reprinted from final submission with permission. Wright, W. C. et al. Clobetasol
Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5. J
Med Chem 63, 1415-1433, https://doi.org/10.1021/acs.jmedchem.9b02067 (2020).180
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inhibitors87,88. Interestingly, among the numerous overlapping substrates, a few
compounds, including the anticancer drug vincristine and the immunosuppressant
tacrolimus have been reported which characterize the selective catalytic activity of
CYP3A57,92,96,151. These compounds are metabolized to a greater extent by CYP3A5 than
by CYP3A4. Moreover, the N-oxide metabolite of the phosphodiesterase inhibitor T1032 has been reported to be catalyzed almost exclusively by CYP3A5, further
demonstrating the distinct function of the enzyme91. Unsurprisingly, each of these
compounds has a different chemical structure, upending the notion that this selective
activity is chemotype-dependent. The demonstration that CYP3A5 selectively
metabolizes certain compounds, however few, suggests that CYP3A5 plays a discrete
role which might potentially be selectively targeted. A compound capable of selectively
inhibiting CYP3A5 will be important for circumventing the inaccurate assignment of
cumulative enzymatic activity to CYP3A4 alone, as well as for delineating between the
two homologs. Such an inhibitor could prove especially beneficial in cases in which
CYP3A5 is the target (e.g., when extrahepatic CYP3A5 is elevated and causes drug
resistance) but CYP3A4 inhibition should be avoided (e.g., so as not to alter normal drug
metabolism in the liver).
Here, we exploited high-throughput screening techniques to identify a selective
inhibitor of CYP3A5. The compound we identified, clobetasol propionate (abbreviated
hereafter as clobetasol), can potently block CYP3A5 catalytic activity without inhibiting
CYP3A4 or other major CYPs. We further identified pancreatic cancer cell lines as
suitable models for studying the selective modulation of CYP3A5 in vitro. Clobetasol
proved to be a nontoxic, potent, and selective inhibitor of CYP3A5 in these cells. We
leveraged molecular dynamics (MD) simulations to predict the potential mechanism of
CYP3A5-selective inhibition. Our simulations suggested that clobetasol resides closely to
the heme group in CYP3A5 but binds to CYP3A4 too distally from the heme in that
protein for effective clobetasol–heme interaction to occur. This computational prediction
is consistent with the essential role of heme in the catalytic activity of CYPs, and it was
further supported experimentally with multiple biophysical techniques, including UV–
visible spectroscopy and electron paramagnetic resonance (EPR) analyses, which can
detect the heme-dependent interactions with compounds. Although it has been suggested
that identifying a CYP3A5-selective inhibitor would be challenging because of the high
structural similarity between CYP3A4 and CYP3A59,90, our work demonstrates that it is
indeed feasible. We anticipate that the structural basis and mechanistic insights revealed
by this work will aid in the further development of CYP3A5-selective inhibitors,
facilitate further investigations of the structural and functional regulation of CYP3A4 and
CYP3A5, and enable exploration of the therapeutic potential of targeting CYP3A5.
High-Throughput Screening Identifies Clobetasol as a Selective CYP3A5 Inhibitor
The high degree of structural similarity between CYP3A4 and CYP3A5 makes it
challenging to use a structure-based approach to design a CYP3A5-selective inhibitor.
Therefore, to search for potential selective CYP3A5 inhibitors, we first used a
luminescence-based enzymatic assay to screen and identify inhibitors of the catalytic
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function of CYP3A5. We then eliminated those compounds which also inhibited
CYP3A4. The assay we used leverages the ability of CYP3A5 to metabolize a “proluciferin” substrate into D-luciferin, which is then converted into luminescence when
luciferase is added to the system. For the primary screen, we used the St. Jude bioactive
compound library of 11,200 total compounds, which contains FDA-approved drugs, drug
candidates, and other compounds with known activity152,153. The propensity of a given
small molecule to inhibit CYP3A5 was clear; hundreds of compounds showed greater
than 50% inhibition at the final tested concentration of 5 µM (Figure 2-1a). To confirm
the CYP3A5-inhibitory activity and determine which of these compounds were selective
for CYP3A5, we chose compounds from the primary screen that conferred at least 60%
CYP3A5 inhibition and evaluated them in dose-response analyses. The 252 chosen
compounds were then screened against CYP3A4 and CYP3A5 in parallel, using the exact
same conditions for each (described in the Methods section). As a demonstration of
nonselective inhibition, we tested the antiretroviral compound ritonavir—a known
inhibitor of the CYP3A family63 and the only compound to have been co-crystalized with
both CYP3A4154 and CYP3A5117. Ritonavir-mediated inhibition aligned with values
reported in the literature58,155, and the inhibitory curves demonstrated high potency for
each enzyme (Figure 2-1b). A systematic comparison of all the dose-response curves led
to the identification of clobetasol propionate (clobetasol) as a potent and selective
CYP3A5 inhibitor. Clobetasol showed the greatest selective inhibition, having IC50
values of 0.206 µM for CYP3A5 and 15.6 µM for CYP3A4 (Figure 2-1b). While a few
other compounds from the screen demonstrated comparatively marginal selective
inhibition, none could match the approximately 76-fold CYP3A4/CYP3A5 IC50 ratio of
clobetasol. Interestingly, clobetasol contains a four-ring steroid scaffold that is analogous
to several known substrates of CYP3A5 within the same drug class156 (Figure 2-1c).
To further demonstrate the CYP3A5-selective inhibition of clobetasol, we
compared the effect to CYP3A4 using clobetasol at a concentration of 1.8 µM (the IC90
concentration for CYP3A5) and used the same concentration of ketoconazole (the goldstandard pan-CYP3A inhibitor157 that served as a normalization control in our
biochemical assays). At 1.8 µM, clobetasol inhibited CYP3A5 by 90%, but no inhibition
of CYP3A4 was observed (Figure 2-1d). As expected, the same concentration of
ketoconazole completely inhibited both enzymes (Figure 2-1d). Although clobetasol
demonstrated remarkable selectivity for CYP3A5 as compared to CYP3A4, we wanted to
test whether it inhibited the catalytic activity of other major human CYPs. We screened
clobetasol against CYP3A4 and a panel of six other human CYPs (CYP1A2, 2B6, 2C8,
2C9, 2C19, and 2D6) recommended by the FDA for drug–drug interaction testing for
candidate pharmaceuticals144,145. Each of these enzymes was tested for catalytic inhibition
by directly measuring the formation of product derived from its own substrate. In the case
of CYP3A4, we tested the two structurally unrelated substrates midazolam and
testosterone, as recommended by the FDA144,145. Not only was CYP3A4-mediated
catalysis of these substrates uninhibited by 1.8 µM clobetasol but other major CYPs also
showed little or no inhibition (Figure 2-1e). Taken together, these data suggest that
clobetasol is a potent and selective inhibitor of CYP3A5 in biochemical systems.
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Figure 2-1.

Clobetasol propionate is a potent and selective inhibitor of CYP3A5.

(a) CYP3A5 inhibition profile of the St. Jude bioactive library when screened at a
concentration of 5 µM. Compounds selected for downstream dose-response testing (those
having ≥60% CYP3A5 inhibition) are shown between the gray dotted lines. The green
circle indicates clobetasol. (b) Dose-response curves for CYP3A4 and CYP3A5 with
ritonavir (Rit) or clobetasol (Clob). IC50 values for each curve are shown in parenthesis.
The IC90 for clobetasol–CYP3A5 are shown in red text. (c) Chemical structure of
clobetasol. (d) Inhibition of CYP3A4 or CYP3A5 by using 1.89 µM ketoconazole (Keto)
or clobetasol (Clob). The DMSO concentration is 0.1%. *** P ≤ 0.0001, ns = not
significant (P ≥ 0.05); one-way analysis of variance (ANOVA). (e) Inhibition profile of
1.85 µM clobetasol against a panel of major human CYPs.
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Pancreatic Cancer Is an Appropriate and Clinically Relevant Model for Studying
Selective Modulation of CYP3A5
After validating clobetasol as a CYP3A5-selective inhibitor in biochemical
assays, we next sought to determine whether this selectivity was maintained in cell-based
systems. Hepatocellular carcinoma serves as a widely used model for studying CYPrelated biology, including that of the CYP3A family158-162. However, although CYP3A5
is expressed appreciably in hepatocellular carcinoma, the (often higher) expression of
CYP3A4 makes delineation between these homologs complex and arduous. Accordingly,
we needed a model system that expressed CYP3A5 but lacked CYP3A4 expression. To
this end, we turned to the PanCancer analysis project from The Cancer Genome Atlas
(TCGA), which hosts RNA-seq datasets derived from more than 10,000 tumor samples
spanning 33 different cancer types163. We reanalyzed all data from this project by using
our in-house pipeline (our stepwise protocol is made available in Protocol Exchange164)
and ranked each cancer type according to the level of CYP3A5 expression. As expected,
the liver and hepatocellular carcinoma (LIHC) cohort exhibited the highest CYP3A5
expression, followed by the bile duct (CHOL) and pancreatic (PAAD) cancer cohorts
(Figure 2-2a). Conversely, CYP3A4 expression was primarily contained within the
LIHC and CHOL cancers (Figure 2-3a). In view of the apparent selective overexpression
of CYP3A5 in pancreatic cancer, we decided to pursue our studies using cell models of
this type. Moreover, CYP3A5 has been reported to be overexpressed in pancreatic
adenocarcinoma and to mediate its chemoresistance9, adding a clinical significance to
studying CYP3A5-mediated drug metabolism in this cancer type.
Clobetasol Selectively Inhibits CYP3A5 in Cells
To determine whether clobetasol inhibited CYP3A5 in a cell-based context, we
modulated the expression of CYP3A5 and/or CYP3A4 in parental AsPC-1 cells (referred
to as wild-type, or WT), which express high levels of endogenous CYP3A5 but no
detectable CYP3A4. To further elevate CYP3A5 levels, we produced doxycycline (Dox)inducible CYP3A5 overexpression in AsPC-1 parental cells (hereafter referred to as “WT
+ 3A5OE” cells). We also used CRISPR/Cas9 technology to knock out CYP3A5 from the
parental AsPC-1 cells (a total CYP3A5 genetic deletion). In these AsPC-1CYP3A5−/− cells
(hereafter abbreviated as 3A5−/− cells), we also produced doxycycline inducible
CYP3A4- and CYP3A5-overexpression systems (referred to as “3A5−/− + 3A4OE” and
“3A5−/− + 3A5OE” cells, respectively). We validated each cell line by measuring and
quantifying the relevant protein expression. As expected, the results (Figure 2-4a)
demonstrated (1) that the 3A5−/− cells had no detectable CYP3A5 protein, (2) that “WT +
3A5OE” cells could be induced to express a higher level of CYP3A5, (3) that
“3A5−/− + 3A5OE” cells could be induced to express CYP3A5 at a level comparable to
that in “WT + 3A5OE” cells, and (4) that CYP3A4 could be successfully overexpressed in
the 3A5−/− cells upon induction (“3A5−/− + 3A4OE” cells). To probe for CYP3A4 or
CYP3A5 catalytic activity, we treated these cell lines with midazolam and measured the
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Figure 2-2. CYP3A5 is over-expressed in pancreatic cancer models and AsPC-1
cells are ideal for studying CYP3A5 modulation.
(a) Expression of CYP3A5 across all cancers within the PanCancer dataset from The
Cancer Genome Atlas (TCGA). Expression is derived from 10,534 tumor samples across
33 cancers and is ranked by median values. The pancreatic adenocarcinoma cohort
(PAAD) is highlighted in red. (b) CYP3A5 expression in pancreatic adenocarcinoma cell
lines compared to that in the noncancerous pancreatic cell line HPNE. *** P ≤ 0.0001, ns
= not significant (P ≥ 0.05); t statistic–derived P values adjusted by the BenjaminiHochberg false discovery rate. (c) Expression of the xenobiotic-metabolizing CYPs from
all pancreatic adenocarcinoma and control cell lines. Units of expression for all panels are
log2 (normalized CPM+1).
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Figure 2-3. Normalized expression of CYP3A4 and CYP3A5 across various
cancer types.
(a) CYP3A4 (left) and CYP3A5 (right) expression across all TCGA PanCancer cohort
types, with GAPDH (right) shown as a housekeeping example. All data were normalized
according to our RNA-seq reprocessing protocol (available in the protocol exchange:
http://doi.org/10.21203/rs.2.16081/v1). (b) TCGA PanCancer cohort abbreviations.

24

Figure 2-4.

Clobetasol selectively inhibits CYP3A5 in vitro.

(a) Representative Western blots of CYP3A5 (top 3 panels) or CYP3A4 (bottom panel).
Corresponding quantifications are shown to the right. Quantification was derived from
triplicate experiments. *** P ≤ 0.0001; unpaired two-tailed t-test. The relative intensity of
WT, WT + 3A5OE (+Dox), 3A5−/− + 3A5OE (+Dox) and 3A5−/− + 3A4OE (+Dox) was
set as 1.0, as indicated in each panel. Dox, doxycycline (100 ng/mL). (b) CYP3A4 or
CYP3A5 activity measured by 1-hydroxymidazolam formation. All panels were
normalized to the DMSO control as 100% activity. (c) Western blot of CYP3A4 or
CYP3A5 expression after 24 h treatment with DMSO (left), 1 µM ketoconazole (Keto,
middle), or 1 µM clobetasol (Clob, right). CYP3A4 is indicated by the slightly higher
bands (star icon); the antibody is known to also detect CYP3A5. Quantification is shown
below the gel images, with DMSO treatment set as 1.0. *** P ≤ 0.0001, ** P ≤ 0.005, *
P ≤ 0.05, and ns = not significant (P ≥ 0.05); One way ANOVA with Tukey adjustment.
(d) CYP3A-mediated activity across all cell lines, showing the relative catalytic
contribution; all samples were treated with the same concentration of DMSO for 24 h.
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product formation via liquid chromatography with tandem mass spectrometry (LCMS/MS). Midazolam is a well-established substrate of CYP3A4 and CYP3A5144, and the
CYP3A-catalyzed 1-hydroxymidazolam product (1OH-MDZ) is readily amenable to
detection by LC-MS/MS81,165,166. Furthermore, because no other enzyme has been
reported to catalyze the formation of 1OH-MDZ, the presence of this product is generally
attributed directly to CYP3A activity. In experiments using parental AsPC-1 (WT) cells,
which have high endogenous CYP3A5 expression but no CYP3A4 expression, clobetasol
produced a sigmoidal dose-response inhibition curve (Figure 2-4b, upper left).
Surprisingly, clobetasol was even slightly more potent at inhibiting CYP3A5 activity than
was the control compound, ketoconazole (a gold-standard, nonselective pan-CYP3A
inhibitor). When we probed for activity in the 3A5−/− cells, we found CYP3A5 activity to
be totally abolished, as indicated by the absence of detectable 1OH-MDZ formation
(Figure 2-4b, upper right), thus providing evidence that CYP3A5 was completely
knocked out, and indeed no other enzyme is able to catalyze the formation of 1OH-MDZ
in the 3A5−/− cells. When CYP3A5 was induced (+Dox) to overexpress in either WT or
3A5−/− cells, midazolam metabolism occurred, and both clobetasol and ketoconazole
inhibited the CYP3A5 activity (Figure 2-4b, middle panels). Having demonstrated
clobetasol to be a potent inhibitor of CYP3A5 catalytic activity in cells, we sought to test
its selectivity by repeating the experiment using 3A5−/− cells overexpressing CYP3A4. As
expected, ketoconazole proved to be a potent and nonselective inhibitor, whereas
clobetasol displayed remarkable selectivity and completely avoided CYP3A4 inhibition
(Figure 2-4b, bottom right). Interestingly, at higher tested concentrations, clobetasol
appeared to increase the enzymatic activity of CYP3A4, producing higher levels of 1OHMDZ than were present at baseline (Figure 2-4b, bottom right). Although this
phenomenon occurred only with higher concentrations of clobetasol, we found the result
interesting and followed it up by examining whether clobetasol increased CYP3A4
protein levels. As shown in Figure 2-4c, clobetasol did not increase the protein level of
CYP3A4 (note that the anti-CYP3A4 antibody detects both CYP3A4 [marked with a star]
and CYP3A5). Interestingly, ketoconazole at a concentration of 1 µM increased CYP3A4
protein expression, but this had no effect on our activity assay because the tested
concentration of 1 µM completely abolished CYP3A4 activity. The compounds used did
not affect cell growth in any cell line that we tested. Moreover, we tested the catalytic
activity of each DMSO-treated cell line by monitoring the generation of 1OH-MDZ in
the absence of compound treatment. Our results showed that the actual catalytic activity
of CYP3A4 in the “3A5−/− + 3A4OE” cells was less than 10% of that of CYP3A5 in the
“3A5−/− + 3A5OE” cells (Figure 2-4d). Together, these data demonstrate that clobetasol is
a potent and selective inhibitor of CYP3A5 in the context of relevant cell models.
Molecular Dynamics Simulations Predict the Mechanism of Selective Inhibition by
Clobetasol
We next asked how clobetasol achieved selectivity between such highly
homologous enzymes as CYP3A4 and CYP3A5. We hypothesized that the selectivity of
clobetasol was in part due to the subtle differences in their active site shapes which were
recently reported167. Furthermore, we reasoned that clobetasol probably interacted in
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some way with the heme moiety of CYP3A5, but not with that of CYP3A4. Catalytic
activation of CYPs occurs through single electron reduction of the CYP heme iron to its
ferrous state, enabling binding of dioxygen. A further reduction and two subsequent
protonation reactions facilitate the production of the reactive iron-oxo species compound
I, which oxidatively attacks the bound substrate to form the product168. CYPs can also be
inhibited by the binding of inhibitors that coordinate to the CYP heme iron169.
Prototypical inhibitors such as ketoconazole function by forming tight, direct interactions
with the heme iron and by blocking access to potential substrates154,111,170,171. To obtain
insight into whether this might be the mechanism underlying the CYP3A5 selectivity of
clobetasol, we used molecular dynamics (MD) simulations. We started by docking
clobetasol into CYP3A4 and CYP3A5. Fortunately, both enzymes have been crystalized
with the same ligand (ritonavir154,117), which provided us with a solid starting point for
our in silico studies. As expected, superimposing the two structures revealed no
significant differences in their secondary structure (Figure 2-5, upper panels).
Interestingly, docking results produced only one pose of clobetasol for both CYP3A4 and
CYP3A5; however, the ligand adopted a different orientation within their active sites
(Figure 2-5, lower panels). To circumvent any bias in binding estimation as a result of
starting structures being forced into low-energy, non-physiologically relevant
conformations, we ran MD simulations independently for the CYP3A4–clobetasol and
CYP3A5–clobetasol structures and ensured that each system had properly equilibrated by
monitoring the root mean squared deviation (RMSD) (Figure 2-6). Additionally, we
solvated the systems in the same water-based solvent model, ran 200-nanosecond (ns)
simulations for each, and kept all other parameters the same between systems to enable
direct comparisons (as detailed in the Methods section).
Our simulations showed clear differences between the interactions of clobetasol
with CYP3A4 and its interactions with CYP3A5. Clobetasol could bind to CYP3A4, but
it preferred an area of the active site too distant from the heme group to be considered a
classical inhibitor (Figure 2-7a, upper panel). Remarkably, clobetasol was stabilized at a
sufficient distance from the heme in CYP3A4 for water to enter the cavity from the
solvent, and we observed a water molecule become stabilized on the heme iron in the
distal position (Figure 2-7a, upper panel). A water molecule coordinated in this way is
representative of the resting state of the enzyme53,172,173, and our MD-derived CYP3A4–
clobetasol structure closely matched the published crystal structure of water-bound
CYP3A4116 (Figure 2-8). Conversely, clobetasol interacted with the active site in closer
proximity to the heme in CYP3A5 than to that in CYP3A4 (Figure 2-7a, lower panel).
Moreover, we observed this heme-ligand interaction as stable and able to be maintained
over the course of the simulation.
To predict the residues with which clobetasol might be interacting inside the
active site of CYP3A4 or CYP3A5, we quantified the percentage interaction across both
simulations and looked at the interaction types (Figure 2-7b). We also measured the
binding stability of clobetasol itself as a function of relative movement by using the root
mean squared fluctuation (RMSF) metric. Quantifying the RMSF showed that most
atoms of clobetasol fluctuated less in CYP3A5 than in CYP3A4; these included the
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Figure 2-5.

Overlay of clobetasol docked into CYP3A4 and CYP3A5.

Overlay of secondary structures for CYP3A4 (slate ) and CYP3A5 (raspberry) illustrating
the similarity of the structures (upper panels) and the differing binding orientations of
clobetasol (lower panels).
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Figure 2-6.

RMSD of CYP3A4 and CYP3A5 molecular dynamics simulations.

Root mean square deviation (RMSD) in Ångstroms of the CYP3A4 (blue) and CYP3A5
(red) molecular dynamics simulations. RMSD was measured based on α-carbon atoms.
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Figure 2-7. Molecular dynamics simulations suggest that clobetasol forms a hemeligand coordination in CYP3A5 but not in CYP3A4.
(a) Snapshots from stable segments of simulations showing clobetasol bound to 3A4 (top)
or 3A5 (bottom). (b) % residue interaction diagram demonstrating the residues interacting
with clobetasol in 3A4 (left) or 3A5 (right). Only residues with a combined 3A4+3A5
interaction of ≥1% over the simulation course are shown. (c) The root mean squared
fluctuation (RMSF) of clobetasol for 3A4 (blue) or 3A5 (red) simulations.Star (*)
represents the carbonyl oxygen closest to the heme. (d) Distance measurement of the
closest non-hydrogen atom of clobetasol to the heme iron of 3A4 (blue) or 3A5 (red) over
simulations. (e) Docked poses of clobetasol in the 3A4 (left) or 3A5 (middle) active sites,
with 5-Å binding sites shown in gray mesh. The superimposed structures are rotated to
show the active site differences (right), which are shown in slate gray (for 3A4) or
raspberry red (for 3A5) mesh.
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Figure 2-8.

Overlay of crystalized and simulated water-bound CYP3A4.

(a) CYP3A4 bound to a water molecule from a published crystal structure (PDB:4I3Q).
(b) The molecular dynamics simulation of CYP3A4 bound to clobetasol. (c) The two
structures superimposed.
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Carbonyl-(C=O) oxygen atoms, closest to the heme iron in CYP3A5 (Figure 2-7c). This
finding can be attributed to clobetasol binding more stably (or moving less) in CYP3A5
than in CYP3A4. Additionally, we wanted to measure the clobetasol–heme distance in
both simulations, since proximity to the heme group is such a hallmark of effective
substrates and inhibitors174-176. We measured the clobetasol–heme distance for every
frame of the simulation and observed that clobetasol was closer to the heme in CYP3A5
than in CYP3A4 (Figure 2-7d). The ability of clobetasol to preferentially and stably
coordinate with the heme iron of CYP3A5 but not that of CYP3A4, thereby blocking
solvent access and presumably serving as the mechanism of selective inhibition, was
puzzling. We investigated why this might occur by examining the active site shapes of
each enzyme. As reported when the crystal structure of CYP3A5 was first solved, its
active site is slightly taller and narrower than that of CYP3A4117,167. Indeed, this
difference was sufficient to permit clobetasol to adopt a vertical binding orientation in
CYP3A5, as compared to its more horizontal orientation in CYP3A4 (Figure 2-7e, left
and middle). Furthermore, neither active site could reciprocate its homolog’s
conformation to clobetasol, since the ligand would clash with the ceiling of the cavity of
CYP3A4 or with the wall of the cavity of CYP3A5 (Figure 2-7e, right). Collectively, our
in silico data have presented a model providing predictive insights into how and why
clobetasol selectively inhibits CYP3A5.
Differential Interaction of Clobetasol with the Heme in CYP3A4 and CYP3A5
To determine experimentally the direct interaction of clobetasol with CYP3A4
and CYP3A5, we performed UV-visible spectroscopic analysis of clobetasol with each of
these CYPs and compared the results to those obtained with their bona fide inhibitor
ketoconazole157 and substrate midazolam177 using the recombinant purified enzymes.
CYPs possess a prosthetic heme b group that is essential for their catalytic activity.
Ligand interactions involving the heme in CYPs can be monitored by UV–visible
spectroscopy, based on the ability of the ligands to induce either a type I Soret shift (blue
shift), reflecting the conversion of the low-spin (LS) heme iron to the high-spin (HS)
state through binding of a substrate, resulting in the displacement of the axial water
ligand; or a type II Soret shift (red shift), typically occurring through the binding of an
inhibitor that displaces the axial water ligand and coordinates to the heme iron (Figure
2-9 upper panels). The titration of clobetasol and midazolam with CYP3A5 in both cases
produced a typical type I CYP spectral shift with a Soret band shift from 417 nm (LS) to
approximately 395 nm (HS) (Figure 2-9c and Figure 2-10). As expected, titration of
ketoconazole with CYP3A5 produced a typical type II (LS) spectrum with a Soret band
shift from 417 nm to 424 nm (Figure 2-9b). To determine the dissociation constant, the
changes in the absorbance spectra of the heme-bound complex for both the clobetasol and
ketoconazole titrations were determined by absorbance difference spectral titrations
(Figure 2-10). Spectral data were obtained by successive additions of clobetasol or
ketoconazole until no further heme absorbance change was observed. Thereafter, in each
case, absorbance difference spectra were generated by subtracting the initial (ligand-free)
spectrum from each successive spectrum, and then identifying the absorbance maximum
(peak) and minimum (trough) values. The peak minus trough values were determined
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Figure 2-9.

UV-Vis and EPR spectroscopy of clobetasol binding.

(a1–3) Schematic representation of ligand-induced CYP heme ferric iron (FeIII) transition
spin states from resting (green) to either high spin (blue) or low spin (red) states. (b,c,e,f)
UV-Vis titrations of ketoconazole (Keto) (b,e) and clobetasol (Clob) (c,f) on 3A5 and
CY3A4, respectively. All titrations were normalized (normalized Abs) for easy
comparison. Green, blue or red line and numbering corresponds to the heme state in a1-3.
(d) Plot of clobetasol (Clob) (ΔAbs 386 nm – 418 nm) and ketoconazole (Keto) (ΔAbs
432 nm – 410 nm) induced heme absorption change (ΔAbs of Heme Bound) in 3A5
versus ligand concentration and data fitted with equation 2 (methods) to give a Kd of 0.1
± 0.3 µM and 3.1 ± 0.5 for clobetasol and keto, respectively. (g) Plot of the maximal
clobetasol (ΔAbs 388 nm – 418 nm) and keto (ΔAbs 432 nm – 410 nm) induced heme
absorption change (ΔAbs of Heme Bound) in 3A4 versus ligand concentration. A Kd of
0.9 ± 0.2 µM was calculated for keto. (h,i) EPR spectra for 3A5 and 3A4 in their ligandfree forms and for their complexes with ketoconazole, midazolam, and clobetasol with
colored number labels corresponding to the heme ferric iron (FeIII) state as in a1–3.
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Figure 2-10. Spectral changes of CYP3A4 and CYP3A5 from various compounds.
(a,b) Spectral changes upon titrating midazolam into 5 µM of CYP3A4 (a) and CYP3A5
(b). Absorbance values were normalized to the maximum value in the spectra. Left insets:
Difference spectra showing absorbance changes between the ligand-free and midazolambound states. Right insets: Titration plots fitted to a hyperbola equation. (c–f) Difference
spectra showing absorbance changes between the ligand-free and compound-bound states
for 3A4 and 3A5 proteins. Color scheme: The UV–Vis spectrum for the ligand-free
(resting) state is in green, whereas the spectra for the last titration point are in blue (type
II blue shift) or red (type I red shift).
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from each difference spectrum, and these values were plotted against the relative ligand
concentration, enabling the production of ligand-binding curves, leading to the generation
of the respective dissociation constants (Kd) of 0.1 ± 0.3 µM for clobetasol binding to
CYP3A5 and a Kd of 3.1 ± 0.5 µM for ketoconazole binding to CYP3A5. In addition, a
similar degree of conversion to the ligand bound form was achieved in titrations with
both clobetasol and ketoconazole where both showed a near complete conversion to the
high-spin or inhibitor bound forms respectively albeit at different concentrations of
ligand (Figure 2-9d). In contrast, titrating clobetasol with CYP3A4 produced only a 416
nm. Similar to CYP3A5, ketoconazole induced a type II spectral shift in CYP3A4 with a
Kd value of 0.9 ± 0.2 µM (Figure 2-9e-g and Figure 2-10). These data clearly suggest a
selective heme iron interaction by clobetasol, particularly for CYP3A5.
To further confirm the selective heme interaction of clobetasol with CYP3A5
versus CYP3A4, continuous wave (CW) X-band electron paramagnetic resonance (EPR)
spectra were generated with ligand-free CYP3A4 and CYP3A5 and with these CYPs in
complex with clobetasol, midazolam, and ketoconazole. Ligand-free CYP3A5 produced a
rhombic LS EPR spectrum with g-values of 2.41 (gz), 2.24 (gy), and 1.91 (gx),
respectively, indicative of a single dominant ferric heme species coordinated by a
proximal cysteine thiolate ligand and a weakly coordinated axial water ligand (Figure 29a-h). In ligand-free CYP3A4, a small signal was seen for an HS species with g-values
apparent at 8.17 and 3.56 (the g-values were not labeled in the spectrum), while in
CYP3A5 no such small HS signal was seen in the resting form of the enzyme. The EPR
spectra for CYP3A5 in complex with clobetasol or midazolam revealed spectral signals
consistent with the formation of a five-coordinate HS ferric heme iron state (which
usually indicates the ligand-dependent displacement of the CYP3A5 distal water ligand)
with HS g-values of 8.04/3.65 (with clobetasol) and 8.10/3.56 (with midazolam) (Figure
2-9a-h). A proportion of the LS ferric signals was retained, indicative of the retention of
a water coordinated state in the absence of substrate, with g-values of 2.41/2.24/1.92 for
both clobetasol and midazolam. In contrast, CYP3A4 revealed no new HS formation with
clobetasol; the spectra were consistent with the corresponding LS ligand-free form with
g-values of 2.40/2.24/1.91, indicating the retention of the axial water ligand in the
presence of clobetasol in CYP3A4. However, an HS signal was induced by midazolam
when the compound was bound to the enzyme with HS g-values of 8.17/3.55 and LS gvalues of 2.40/2.24/1.91. As expected, both CYP3A4 and CYP3A5 produced new LS
species when bound to ketoconazole, with g-values of 2.55, 2.49/2.24/1.88 for CYP3A4
and 2.47, 2.42/2.24/1.88 for CYP3A5, which are typical signals seen for a CYP enzyme
with an azole inhibitor bound (Figure 2-9h,i). These data provide further evidence of the
selectivity of clobetasol for CYP3A5.
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CHAPTER 3.

TRANSCRIPTIONAL REGULATION OF CYP3A5

Regulation of CYP3A5 in Pancreatic Cancer Remains Unknown
It is known that CYP3A4 and CYP3A5 are controlled by common regulators in
the widely studied hepatocellular carcinoma model HepG2178. Due to heightened risk of
drug-drug interactions, the subject of CYP3A regulation has been intensely researched in
this context. Pregnane X Receptor (PXR) is a ligand-inducible transcription factor and
serves as the primary regulator of CYP3A in liver - and its induction can lead to
markedly higher expression of these enzymes179. However, the regulation of CYP3A has
not been delineated in extra-hepatic models. CYP3A5 is expressed outside of the liver in
several tissues such as kidney, prostate, intestine, and lung2. The recent report of selective
CYP3A5 over-expression180 and contribution to chemoresistance in pancreatic cancer9
signifies that this enzyme is controlled in a different manner. Based on the only
presently-available report, it is suggested that outside of PXR it’s possible that CYP3A5
is regulated in this cancer by hepatocyte nuclear factor alpha (HNF4α)9. We investigated
this by testing CYP3A5 mRNA and protein levels upon RNAi-mediated knockdown of
PXR and HNF4α. We used the high CYP3A5-expressing pancreatic cancer model AsPC1 and show that neither PXR nor HNF4α control CYP3A5 levels (Figure 3-1a, b).
Additionally, we generated a CRISPR/Cas9-mediated genetic PXR mutant cell line and
sequenced its RNA, along with a wild-type cell line of the same background. It was
evident that the PXR functional mutation had a global effect on transcription, but
CYP3A5 was completely unaffected (Figure 3-1c). Collectively, these data strengthen
the evidence that neither PXR nor HNF4α transcriptionally regulate CYP3A5, and that its
true regulators in this cancer model remain unknown. While we have identified the first
selective CYP3A5 inhibitor which can be used as a means of target validation, there is a
lot of room for improvement before it can be of potential clinical use (its current intended
target is glucocorticoid receptor, for example). Outside of direct inhibition however exists
the possibility of targeting CYP3A5 upstream. This warrants elucidation of its true
transcriptional regulators, both for targeting CYP3A5 and for gaining more insight into
the biology of CYP3A5-expressing cancers.
Development of a Novel Computational Method of Regulator Prediction
Several approaches are available to researchers needing to find which factors
control the expression of a given target. Spanning both computational and experimental
techniques, each has its own set of benefits and limitations. Among the most exhaustive
of experimental approaches is knockdown of the entire genome one-by-one using
expression modulation techniques like RNAi or CRISPR/Cas9. Screening at this scale
requires an assay with target readout and signal window robust enough to be suitable for
high-throughput. By that point the scientific question needs to merit the time and
resources required for a project of such magnitude. Additionally, whole-genome screens
are typically conducted in a single model, limiting the ability to capture regulation
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Figure 3-1.

Neither PXR nor HNF4α control CYP3A5 in AsPC-1 cells.

(a) CYP3A5 mRNA and (b) protein levels upon RNAi-mediated knockdown of PXR or
HNF4α. (c) Volcano plot of transcriptome-wide effects of gene expression mediated by
PXR knockout. CRISPR/Cas9 technology was used to generate a PXR functional
knockout, and data are compared to AsPC-1 WT.
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mechanisms representative of the complex and heterogenous disease. A more casual
option would be to search repositories of ChIP-seq experiments (such as the ENCODE
database181), reverse-querying the data to see if DNA of the target has been bound by any
known proteins. This option is easy to perform and often combines tissue/disease states
for added robustness. However, these databases limit researchers to nucleic acidassociated proteins such as transcription factors, when any number of other non-DNAbinding proteins in a pathway may ultimately regulate a target. Furthermore, ChIP-seq
data is rarely context-specific, and thus interpretation of putative regulators will be
skewed if the target of interest is different across contexts. For example, a ChIP-seq
query for proteins found to bind the CYP3A5 promoter may return PXR as a hit due to
the samples being averaged across tissue and disease. While this may be indicative of
hepatocellular carcinoma for example, it doesn’t hold true in pancreatic cancer.
Experimental approaches that test knockdown of only a subset of genes are
reasonable if the readout is appropriate. For example, if the aim is to search for regulators
of a target’s transcription, post-transcription readouts such as protein imaging or
measuring its downstream function with luminescence (if an enzyme) may not be
appropriate since mRNA, protein, and function do not always correlate. This is especially
the case if the mRNA plays any non-canonical biological role. Another important
consideration is how to come up with the initial list of candidate genes for knockdown.
Choosing curated commercially available siRNA or CRISPR libraries like transcription
factors or cancer-specific genes can drastically reduce the screening size compared to
whole-genome. The downside of this is that each library limits researchers based on a
priori knowledge, whereby genes of unknown or uncharacterized function are excluded.
Computational methods exist to identify putative transcriptional regulators from
sequencing data, potentially outputting a reasonable quantity of gene candidates to test.
The benefits of these methods are that they start from a source of typically heterogenous
data, such as expression data from several cell lines or patient tumor samples. The
limitation is that most stem from inference algorithms which are fundamentally designed
to uncover drivers of a disease, or essential genes – not the specific regulator(s) of a
single target. One such example is the popular Algorithm for the Reconstruction of
Accurate Cellular Networks (ARACNe)182. This method and others (such as Networkbased Bayesian Inference of Drivers or NetBID) successfully address important topics in
disease such as uncovering proteins that drive a given cancer183 or characterize diseasespecific transcriptional activity184. Obtaining regulators of a single target is only a
byproduct of these techniques however and is flawed due the techniques themselves
being designed to address different questions. Additionally, one of the highlights of using
inference is to infer relationships based on known gene functions and/or existing
experimental data. While sometimes helping to narrow down large hit lists, this precludes
these methods from being unbiased.
There is a clear need for a computational method capable of agnostically
predicting transcriptional regulators without inference. Ideally, one would want to know
the pairwise relationships of all genes across all samples within a dataset. Theoretically,
the mathematical operation to calculate these relationships is trivial; Spearman or Pearson
correlations are among the most popular to detect the linear relationships of gene
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products. In practice however, such a brute force approach on a transcriptome-wide level
is challenging due to the substantial computational strain. Non inference-based methods
to understand pairwise relationships of data do exist, such as the tool Weighted Gene
Correlation Network Analysis (WGCNA)185. However, they often take shortcuts either by
heavily filtering the starting data, only considering known transcription factors, avoiding
statistical significance measurements altogether, or modifying expression results to
achieve faster calculations. No current tool is available to overcome all of these
limitations.
We developed a computational pipeline capable of intaking large expression data,
and quickly computing transcriptome-wide pairwise correlations and co-expression
networks to agnostically predict transcriptional regulators of a given target. The resulting
tool is named Correlations Of Large Datasets to Search for Transcriptional Regulators or
COLDSTaR. Co-expression derived from pairwise correlations represents a useful means
to understand how genes behave together across a population186,187. This type of data can
be leveraged for the purpose of predicting which correlated genes may transcriptionally
control a given target. Simplified, co-expression networks generally represent four
possible interpretations. Relative to the gene of interest, a co-expressed gene could be
transcriptionally upstream, transcriptionally downstream, co-regulated with the gene, or
just noise and not truly co-expressed (Figure 3-2a). We incorporate several steps in the
COLDSTaR workflow, which are explained in detail within our methodology. We also
make our code publicly-available in our GitHub repository (github.com/wcharleswright).
A graphical representation of the general workflow can be found in Figure 3-2b.
COLDSTaR takes in large expression data and automatically performs several
steps for normalization. The resulting data are then prepared and filtered for downstream
processes. Of note, no gene is filtered out unless completely unexpressed across 100% of
samples in a set. This is different from other pipelines which often filter genes whose
expression is low in the majority of samples for the purpose of gaining speed and
decreasing workload. Our rationale was that the expression of a given transcriptional
regulator may only need to be very lowly expressed in order to efficiently control its
target. Such relaxed filtering criteria keeps tens of thousands more genes which would
otherwise be discarded. The next step is to calculate the correlations and corresponding
statistical significance. The calculations themselves are straightforward, and we take
advantage of the Spearman rank correlation coefficient (ρ or “rho”) due to its resistance
to outliers when dealing with gene expression data188. The difficulty comes from the
amount of calculations needed. Computing all-by-all correlations requires producing a
matrix of n2 values, where n is equal to the number of genes. A typical number of genes
passing our relaxed filtering criteria is around 35,000, which would require 35,0002 (1.2
billion) calculations each of rho and p-values. This far exceeds the processing and
memory limitations of even large, dedicated computer servers. We overcome this
obstacle by expanding upon block-wise computation to create very large correlation
matrices. Previous research has been conducted for computing such large matrices
through the R framework in a block-wise fashion.189 This method fills a large
preallocated empty matrix with temporary submatrix ‘blocks’ at their corresponding
positions, and ultimately accesses the blocks as they are completed to stitch them into the
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Figure 3-2.

COLDSTaR analysis of pancreatic tumors.

(a) Diagram of typical types of information gained from co-expression networks. (b)
General overview of the COLDSTaR pipeline for automated generation of co-expression
networks based on tumor expression data. (c) Overview of the adjusted p-value
distribution and (d) Spearman’s rho value resulting from the pancreatic adenocarcinoma
cohort of TCGA (n= 183 tumor samples) analyzed by COLDSTaR. (e) Global coexpression network of all threshold-passing correlations. (f-h) Extracted subnetworks of
select transcriptional regulators, and their experimentally validated targets (i) Extracted
subnetwork of CYP3A5. (j) Strongest positive and (k) inverse correlations from the
network. Dots represent Log2(Normalized CPM+1) expression corresponding to a tumor
sample. Regression lines are shown in blue and 95% confidence intervals in gray.
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final matrix. We exploited this technique, modifying it to serve our purpose by
simultaneously calculating Spearman correlations and p-values of our large gene sets.
The next step is to apply a statistical adjustment to the resulting p-values. Statistical
testing in gene expression suffers from the multiple hypothesis problem, which can
dramatically skew statistical significance and lead to misinterpretation190. COLDSTaR
applies a Bonferroni p-value adjustment. This type of correction dramatically lessens the
statistical significance of any given p-value, and is considered to be among the most
conservative of commonly-used corrections191. The rationale for using this method relates
to the ultimate goal of selecting the most likely transcriptional regulators of a given
target. While some correlations which may be biologically true are regarded as
statistically insignificant due to this step, the top results (and thus most likely to be true)
are retained. After statistical refinement, the tool then applies thresholds to the data.
Thresholds are an important part of the workflow to discard co-expression results which
are likely irrelevant. Spearman correlations on an absolute scale (|rho|) range from 0-1,
where higher values indicate tighter correlations and values closer to zero are more
suggestive of there being no linear relationship. While there is no strict rule for a cutoff
as being biologically accurate192, we chose a moderately stringent threshold for the
purpose of keeping a reasonable number of likely true hits, based on empirical testing.
The applied threshold is defined as those correlations of |rho| ≥ 0.6 and adjusted p-value ≤
0.05. Following threshold application, COLDSTaR exports the results as tabular data (a
CSV file) which can be easily searched for a gene of interest. COLDSTaR results can
also answer questions of which genes are most tightly co-expressed (either positively or
inversely) across the entire transcriptome. This is a unique capability, afforded by the
brute force all-by-all computation approach. Finally, we transform the tabular data into a
co-expression network. This is achieved by our network calculation and visualization tool
COLDNet (also available in our GitHub repository). Resulting networks can be generated
easily to see not only all co-expressed genes relative to a gene of interest, but the
relationship to themselves as well. This provides valuable insight especially in the
context of hit selection.
COLDSTaR Analysis of Pancreatic Tumors
To begin our search for predicted CYP3A5 regulators in pancreatic cancer, we
first obtained gene expression data from 183 pancreatic cancer tumors sequenced by The
Cancer Genome Atlas (TCGA)163. We analyzed all data with the COLDSTaR pipeline
and inspected the results. Greater than 300,000 statistically significant threshold-passing
correlations were obtained (Figure 3-2c, d). Most of the correlations were positive,
although a subset was inverse. This may represent transcriptional repression. Since
correlation data were calculated on a transcriptome-wide level, a global network could be
plotted from which to extract subnetworks of interest (Figure 3-2e). While no synthetic
data can be constructed for transcriptional regulation to test the validity of our tool, we
found it reasonable to inspect networks for known examples of regulators and their target
genes as a means of sanity checks. HNF1A is widely implicated in pancreatic cancer193195
. We extracted the HNF1A subnetwork and found several examples of genes known to
be under HNF1A regulation such as MUC13196, FOXA3197, SPINK1193, and HNF4α 197
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among others(Figure 3-2f). We also extracted the subnetwork for ETS1, a wellestablished proto-oncogene transcription factor198 and found examples of known
downstream targets such as MEF2C199, PRDX2200, and ZEB2201 (Figure 3-2g). We were
curious about known non-transcription factor regulators, and decided to extract the
subnetwork of the long noncoding RNA HOTAIR, which is known to transcriptionally
regulate HOX gene clusters202,203. Interestingly, all but one gene in the resulting HOTAIR
network belonged to the HOX family (Figure 3-2h). These networks suggested that
COLDSTaR may be able to predict a list of regulators for CYP3A5. Indeed, we were able
to extract the CYP3A5 subnetwork and obtain various co-expressed gene candidates
along with it (Figure 3-2i). As previously mentioned, one distinguishing feature of our
tool is the resulting all-by-all correlations, which can be used to simply browse which
two genes are most tightly correlated among data spanning hundreds of thousands of
correlations. We found the pancreatic cancer cohort to most tightly co-express IGLC1
and its paralog IGLL5, which are part of the immunoglobulin lambda chain (Figure 32j). The strongest inverse correlation was from ZNF540 and TUBA1C (Figure 3-2k).
When ZNF540 expression is high, TUBA1C is low. Interestingly, ZNF540 is a known
transcriptional repressor204, and TUBA1C is reported as an oncogene205, although no
studies have tied them together. Collectively, COLDSTaR identified known regulatortarget relationships, showed interesting connections between co-expressed genes, and
suggested there could be promise for identifying transcriptional regulators of CYP3A5.
COLDSTaR Captures Transcriptional Regulators of CYP3A5
While COLDSTaR is able to overcome various limitations of other tools, it
remained unvalidated experimentally and was not directly compared to other methods. To
this end, we analyzed the exact same pancreatic cancer expression dataset using two other
methods. NetBID is a systems biology algorithm which measures gene relationships
across samples based on mutual information, and has successfully identified driver genes
and their functions183. cBioPortal is another tool capable of calculating pairwise
correlations without inference206. Like COLDSTaR, cBioPortal can measure Spearman
correlation values across TCGA data to generate pairwise correlations. This repository is
popular, accessible, and easy to use. Unlike COLDSTaR however, cBioPortal does not
re-normalize expression data, cannot calculate all-by-all correlations (and thus only
returns co-expressed results for one gene of interest at a time), and cannot produce coexpression networks. We removed these features from COLDSTaR in an effort to
reproduce the cBioPortal method, only differing by applying the COLDSTaR threshold
since cBioPortal’s results are not subject to any cutoffs and would produces thousands of
hits. We refer to this modified cBioPortal method as ‘Correlation only’.
Each method was tested for its ability to predict transcriptional regulators of
CYP3A5. All 3 methods returned candidate genes with corresponding commerciallyavailable siRNAs that could be experimentally tested downstream. NetBID produced 173
candidates, Correlation only method produced 40, and COLDSTaR produced 60 (Figure
3-3a). Interestingly, there was relatively low overlap in predicted CYP3A5 regulators
between the three methods, highlighting their differences in design. We inspected the
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Figure 3-3.

COLDSTaR captures transcriptional regulators of CYP3A5.

(a) Venn diagram of predicted CYP3A5 transcriptional regulators produced by the
inference algorithm NetBID, correlation only method, and COLDSTaR. Hits displayed
are those with commercially available siRNAs. (b) The distribution of predicted
regulators in units of mutual information (for NetBID) or Spearman’s rho (corr. only and
COLDSTaR). (c) CYP3A5 expression across 1,248 cell lines obtained from depmap
(depmap.org). Units are Log2(TPM+1). (d-g) mRNA-based screen of predicted
regulators from each of the three methods, performed in AsPC-1 cells. Assay normalized
to siCYP3A5 and siNT. Each assay performed in triplicate. (h) Number of hits with
>50% or >70% CYP3A5 KD by prediction method. (i) Top 10 hits from screen (all
methods combined) with their corresponding protein class and (j) %CYP3A5 KD and
method origin.
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distribution of these predictions among the three methods and saw they spanned various
scores, either for mutual information (NetBID) or Spearman’s rho (Corr only and
COLDSTaR) (Figure 3-3b). This suggests that in cases where numbers of candidates are
produced beyond validation capabilities, the lists could be ranked to narrow selections.
For our purposes we wanted to exhaustively test our method against others and decided to
continue with 100% of hits identified from each method. We then searched for an
appropriate cell model in which to screen candidate CYP3A5 regulators. We searched the
largest repository of RNA-seq data for cell lines, DepMap portal207. Of the 1,248 cell
lines AsPC-1 cells had the highest CYP3A5 expression (Figure 3-3c), which we chose to
continue forward with. We next knocked down all candidates using siRNA in these cells
and measured the resulting effect on CYP3A5 mRNA. All three methods produced hits
which both increased and decreased CYP3A5 levels (Figure 3-3d-f). When all 237
siRNA were combined and assigned the method they were derived from, COLDSTaR
hits were enriched as the best in terms of CYP3A5 knockdown (Figure 3-3g). When
evaluating hits in the categories of > 50% or > 70% CYP3A5 knockdown, COLDSTaR
remained the best (Figure 3-3h). We inspected the top 10 screening hits (regardless of
which method identified them) and noticed that the majority of them were not
transcription factors (Figure 3-3i). These hits spanned from 68% CYP3A5 knockdown to
> 100% (better than siCYP3A5) and were all exclusively identified by COLDSTaR, with
the exception of HNF1B (identified by NetBID and COLDSTaR) and ZXDB (identified
exclusively by NetBID). These results highlighted the utility of our new tool and showed
promise for potentially identifying CYP3A5 transcriptional regulators.
Knockdown of Predicted Transcriptional Regulators Ablates CYP3A5 mRNA
Expression
Results obtained from screening-level experiments can be spurious and need to be
validated. To this end we tested the top 10 putative hits (Figure 3-3i) using pooled
siRNA in AsPC-1 cells. Some of the hits showed very promising results, even
approaching total knockdown (Figure 3-4a). We were interested to see that siCYP3A4
also decreased CYP3A5, but this is likely attributed to off-target effects considering the
high homology between the homologs. We next decided to pursue the hits which
decreased CYP3A5 levels ≥ 50% by deconvoluting them in an effort to decrease offtarget effects and increase knockdown (Figure 3-4b). Each of the 4 hits showed striking
CYP3A5 knockdown (Figure 3-4b) and were statistically significant compared to the
siNT control (Figure 3-4c). Interestingly, the top two hits were not transcription factors.
GUCA2B is a peptide ligand of the Guanylate Cyclase 2C receptor208, and FABP1 is a
fatty acid-binding enzyme209. Remarkably, these two hits displayed complete CYP3A5
knockdown and serve as indication that they tightly control CYP3A5 transcription.
Furthermore, these hits were identified exclusively by COLDSTaR and also highlight the
importance of considering non-DNA-binding candidates. Finally, we tested the ability of
our hits to decrease 3A5 protein levels. While this is not the goal of our tool, we were
interested to probe protein levels as an added layer of information. The top 2 hits which
completely ablate CYP3A5 mRNA expression also drastically decrease CYP3A5 protein
(Figure 3-4d). The other two hits didn’t show much effect on protein knockdown,
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Figure 3-4. Knockdown of predicted transcriptional regulators ablates CYP3A5
mRNA expression.
(a) Normalized CYP3A5 KD upon treatment with pooled siRNAs representing top 10
screening hits. Transfection was performed in AsPC-1 cells. (b) Deconvolution of siRNA
hits from panel a (defined by ≥ 50% CYP3A5 KD). Pink bars represent the individual
best performing siRNA. (c) Statistical comparison of the deconvoluted siRNAs and
siCYP3A5 control compared to siNT. *** P ≤ 0.0001, one-way analysis of variance
(ANOVA)
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possibly indicating they act primarily on the mRNA level. Collectively, our results
demonstrate that COLDSTaR successfully identified 4 transcriptional regulators of
CYP3A5 in a pancreatic cancer model. These regulators are unreported in the context of
regulating CYP3A5, and warrant further investigation, particularly in the case of
targeting CYP3A5 in disease.
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CHAPTER 4.

METHODOLOGY*

Compounds Used
All compounds were obtained from commercial sources and the purity was 95%
or higher. The compound name, vendor, catalog number, and analytical method used to
determine purity are: Ritonavir, Toronto Research Chemicals, R535000, 1H NMR; 1hydroxymidazolam, Cayman Chemical, 10385, 1H NMR; Clobetasol propionate, AK
Scientific, F535, HPLC; Ketoconazole, Abovchem, AC513267, 1H NMR; Midazolam,
U.S. Pharmacopeia, 1443599, UHPLC and LC-MS/MS.
CYP3A4 and CYP3A5 Biochemical Inhibition
To measure the inhibition of CYP3A4 or CYP3A5, the P450-Glo luminescence
assay using the substrate Luciferin-IPA was purchased from Promega (Madison, WI; cat.
no. V9002). Supersomes from Corning Life Sciences (Tewksbury, MA) were used as the
source of purified recombinant human enzymes; they contained P450 oxidoreductase
(POR), cytochrome b5, and either CYP3A4 (Corning, cat. no. 456202) or CYP3A5
(Corning, cat. no. 456256), each at 1000 pmol/mL. Insect cell control supersomes were
used as a negative assay control (Corning, cat. no. 456200). The assay protocol was
performed in accordance with the P450-Glo manual, using final concentrations of 0.1
pmol of enzyme, 100 mM KPO4 (pH 7.4) buffer, and 3 µM Luciferin-IPA as substrate.
Upon the reactions being initiated by the addition of NADPH, the plates were incubated
for 10 min at 37 °C. Reactions were then quenched for 20 min at room temperature, using
the luciferin detection reagent. Luminescence was recorded with an EnVision 2102
Multilabel Plate Reader from PerkinElmer Life Sciences (Hopkinton, MA). All assays
were performed using 384-well, polystyrene, white, opaque, non-treated plates (Corning,
cat. no. 8850BC). The percentage inhibition was normalized to the average of six
replicates containing either 30 µM ketoconazole (100% inhibition) or DMSO (0%
inhibition) within each plate. The final concentration of DMSO for all compound and
control wells of the assay plates was 0.1%.
For primary screening, an in-house library of bioactive compounds (n = 11,200,
but some compounds are redundant) having diverse bioactivity was screened at a single
concentration of 5 µM against CYP3A5. Compounds conferring at least 60% inhibition
-------------------* Portions of chapter from previously published article; pre-print submission reprinted
with permission of American Chemical Society. Wright, W. C. et al. Clobetasol
Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5. J
Med Chem 63, 1415-1433, https://doi.org/10.1021/acs.jmedchem.9b02067 (2020).180
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(n = 423; 252 unique compounds) were then screened in a dose-response format against
CYP3A4 and CYP3A5 in parallel. All compounds were screened in technical triplicate as
1:2 dilutions with concentrations ranging from 0.0073 µM to 15 µM. Scale
transformation, normalization, curve fitting, and inhibitory concentration calculations
were performed using GraphPad Prism 8.2.0 (GraphPad Software, La Jolla, CA).
Specifically, the “log(inhibitor) vs. normalized response” equation was used to fit a
standard slope curve based on normalized data and to subsequently extrapolate IC50 and
IC90 values. Statistical comparisons were also performed in GraphPad Prism, using oneway ANOVA assuming equal standard deviations and comparing mean values.
Clobetasol Inhibition Profiling Against a Panel of Major Human CYPs
Clobetasol propionate was prepared as a 25 mM stock solution in DMSO and
stored at −20 °C. The compound was screened against a panel of major human CYPs by
using the cytochrome P450 inhibition service from Cyprotex US, LLC (Watertown, MA).
Serial dilutions of clobetasol were made in acetonitrile:DMSO (9:1) to yield final
concentrations at 1:3 intervals ranging from 0.068 µM to 50 µM. The final DMSO
concentration across all reactions was 0.2%. Clobetasol was incubated with pooled
human liver microsomes (Bioreclamation-IVT, Baltimore, MD) in the presence of 2 mM
NADPH in 100 mM KPO4 buffer, pH 7.4, containing 5 mM MgCl2 and the respective
CYP probe substrate. The final volume of all reactions was 200 μL, and the assay was
performed in technical triplicate. The probe substrate, probe concentration, microsomal
protein concentration, incubation time, and positive control compound for each tested
CYP were as follows: for CYP1A2: tacrine, 5 µM, 0.2 mg/mL, 10 min, αnaphthoflavone; for CYP2B6: bupropion, 100 µM, 0.25 mg/mL, 10 min, ticlopidine; for
CYP2C8: amodiaquine, 5 µM, 0.25 mg/mL, 10 min, quercetin; for CYP2C9,
tolbutamide, 100 µM, 0.5 mg/mL, 15 min, sulfaphenazole; for CYP2C19: mephenytoin,
100 µM, 0.25 mg/mL, 60 min, ticlopidine; for CYP2D6: dextromethorphan, 5 µM, 0.5
mg/mL, 10 min, quinidine; and for CYP3A4: midazolam, 2.5 µM, or testosterone, 50
µM, 0.25 mg/mL, 10 min, ketoconazole. Each reaction mixture was incubated at 37 °C.
Reactions were terminated by adding methanol containing an internal standard for
analytical quantification. Quenched samples were then incubated at 4 °C for 10 min and
centrifuged at 6,102 × RCF. Supernatants were analyzed by LC-MS/MS for the following
metabolites: hydroxytacrine for CYP1A2; hydroxybupropion for CYP2B6;
desethylamodiaquine for CYP2C8; α-hydroxytolbutamide for CYP2C9; 4hydroxymephenytoin for CYP2C19; dextromethorphan for CYP2D6; and 1hydroxymidazolam or 6β-hydroxytestosterone for CYP3A4.
Samples were analyzed using a 5500 QTrap mass spectrometer (AB Sciex,
Framingham, MA) in positive ionization mode, a 1290 Infinity Series autosampler and
solvent delivery system (Agilent, Santa Clara, CA) at 10 °C, and an Acquity UPLC HSS
T3 1.8 µm, 2.1 mm × 50 mm column (Waters, Milford, MA) at 50 °C. For the UPLC
gradient, samples were collected at 0.00, 0.05, 1.00, 1.80, 1.81, and 2.80 min. At the
collection times, the respective flow rates (in mL/min) were 0.6 for all times; the mobile
phase A percentages were 98, 98, 5.0, 5.0, 98, and 98, respectively; and the mobile phase
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B percentages were 2.0, 2.0, 95, 95, 2.0, and 2.0. Mobile phase A consisted of water
containing 0.1% formic acid, and mobile phase B consisted of acetonitrile containing
0.1% formic acid. Injection volumes were 10 µL for all samples.
Data Mining to Profile CYP3A5 Expression Across Cancer Types
To determine the CYP3A5 expression levels in publicly available cancer samples,
data were obtained from the UCSC TOIL recompute210 of samples originating from the
Pan-Cancer analysis project conducted by The Cancer Genome Atlas (TCGA)163.
Expression data from 33 cancer types (10,534 samples) were loaded into the R statistical
environment [www.r-project.org] in the form of gene-level counts produced as the output
of RSEM174. The edgeR package211, with Limma212 and Voom213, was used for linear
modeling, empirical Bayes smoothing, and TMM normalization to produce normalized
expression in units of log2(normalized CPM+1). CYP3A5 expression levels were plotted
using the ggplot2 package214 as ranked levels in descending order according to their
median values. The stepwise data-mining protocol is available in the Protocol
Exchange164.
RNA Extraction and Sequencing
Total RNA was extracted from each cell line by using the Maxwell 16 LEV
automation system and a Maxwell simplyRNA Purification Kit (Promega, cat. no. 1280)
in accordance with the manufacturer’s protocol. The extracted RNA was quantified by
spectrophotometry, using a NanoDrop 8000 spectrophotometer (Thermo Fisher
Scientific, Waltham, MA) to ensure a reading for OD260/OD280 between 1.8 and 2.0.
The RNA quality was further checked by TapeStation 4200 high-sensitivity RNA
screen tape (Agilent, Santa Clara, CA) before library generation. Only high-quality
samples with an RNA integrity number (RIN) of 8 or higher were used to construct the
sequencing library. The RNA was fragmented using fragmentation reagent. For cDNA
synthesis, the first-strand cDNA was generated using random hexamer-primed reverse
transcription, after which the second-strand cDNA was synthesized. Libraries were
prepared from total RNA with the TruSeq Stranded mRNA Library Preparation Kit
(Illumina, San Diego, CA). Libraries were quantified using the Quant-iT PicoGreen
dsDNA Assay (Life Technologies, Carlsbad, CA). One hundred–cycle paired-end
sequencing was performed using an Illumina NovaSeq 6000 System to produce 100 bp
paired-end reads.
RNA-Seq Data Analysis
Raw sequence files were merged across lanes according to sample and subjected
to a first round of quality control by using the FastQC tool
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Illumina universal adapters
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were trimmed from all samples using Trim Galore
(http://www.bioinformatics.babraham.ac.uk/projects/trim_galore/), and samples were
then subjected to a second round of quality control. Reads were mapped to the human
Hg38 reference genome by using Bowtie2215 in sensitive mapping mode. Gene-level
quantification was obtained using RSEM174 to produce raw read counts. The edgeR
package211, with Limma212 and Voom213, was used for linear modeling, empirical Bayes
smoothing, TMM normalization, and all statistical comparisons. All P values were
calculated based on t statistics then adjusted with the Benjamini–Hochberg false
discovery rate. RNA-seq data from all included cell lines are available at the Gene
Expression Omnibus (GEO) repository (accession no. GSE138437).
Cell Culture Method
AsPC-1 wild-type (WT), AsPC-1CYP3A5−/− (3A5−/−), and SU.86.86 cells were
grown in culture in RPMI 1640 medium containing phenol red (Gibco, cat. no. 11875093) with added 10% fetal bovine serum (HyClone, cat. no. SH30071.03), 1% Glutamax
(Gibco, cat. no. 35050-061), and 1% penicillin streptomycin (Gibco, cat. no. 15140-122).
AsPC-1 cells with CYP3A5 overexpression (WT + 3A5OE cells), AsPC-1CYP3A5−/−
cells with CYP3A5 overexpression (“3A5−/− + 3A5OE” cells), and AsPC1CYP3A5−/−cells with CYP3A4 overexpression (“3A5−/− + 3A4OE” cells) were grown
in culture in RPMI 1640 medium containing phenol red (Gibco) with added 10%
tetracycline-free fetal bovine serum (Takara, cat. no. 631101), 2 µg/mL puromycin
(Sigma, cat. no. P9620), 1 mg/mL G418 (Gibco, cat. no. 10131-027), and 1% Glutamax
(Gibco). MIA PaCa-2 cells were grown in culture in DMEM containing phenol red
(Gibco, cat. no. 11965-092) with added 10% fetal bovine serum (HyClone), 1% penicillin
streptomycin (Gibco), and 2.5% horse serum (ATCC, cat. no. 30-2040). PANC-1 cells
were grown in culture DMEM (Gibco) with added 10% fetal bovine serum (HyClone)
and 1% penicillin streptomycin (Gibco). hTERT-HPNE cells were grown in culture in
DMEM containing phenol red (Gibco) with added 5% fetal bovine serum (HyClone), 150
ng/mL puromycin (Sigma), 10 ng/mL human epidermal growth factor (Fisher Scientific,
cat. no. 50400346), and 5.5 mM D-glucose (Sigma, cat. no. G8769). CFPAC-1 cells were
grown in culture in IMDM containing phenol red (Life Technologies, cat. no. 12440-053)
with added 10% fetal bovine serum (HyClone) and 1% penicillin streptomycin (Gibco).
Capan-2 cells were grown in culture in McCoy’s 5A modified medium containing phenol
red (ATCC, cat. no. 30-2007) with added 10% fetal bovine serum (HyClone) and 1%
penicillin streptomycin (Gibco). HPAF-II cells were grown in culture in EMEM
containing phenol red (ATCC, cat. no. 30-2003) with added 10% fetal bovine serum
(HyClone) and 1% penicillin streptomycin (Gibco). Panc 02.13 cells were grown in
culture in RPMI containing phenol red (Gibco) with 15% fetal bovine serum (Gibco), 1%
penicillin streptomycin (Gibco), and 10 units/mL insulin (Sigma, cat. no. 91077C). All
cell lines were obtained from ATCC (Manassas, VA), and all were maintained at 37 °C in
5% CO2. All cell lines have been authenticated by short tandem repeat (STR) DNA
profiling and were routinely verified to be free of mycoplasma contamination.
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Generation of Stable AsPC-1 Cells with Inducible Overexpression of CYP3A4 and
CYP3A5
pLVX-TRE3G-ZsGreen1 (cat. no. 631361) and pLVX-EF1a-TRE3G (cat. no.
631359) were obtained from Clontech Laboratories, Inc. (Mountain View, CA). CYP3A5
cDNA (OriGene RC207432) and CYP3A4 cDNA (OriGene SC125488) were obtained
from OriGene Technologies Inc. (Rockville, MD). The following PCR primers were used
to amplify the CYP3A5 MluI/EcoRI fragment and the CYP3A4 MluI/NdeI fragment for
subcloning into the corresponding sites of the pLVX-TRE3G-ZsGreen1 vector, after gel
extraction and purification using the QIAquick Gel Extraction Kit (cat. no. 28407) from
Qiagen Science Inc. (Germantown, MD):Tet-ZsGreen-3A5-MluI-F: 5′GCCCCCGGGACGCGTGATGGACCTCATCCCAAATTTGG-3′ Tet-ZsGreen-3A5EcoRI-R: 5′-CTACCCGGTAGAATTCTCATTCTCCACTTAGGGTTCCA-3′ TetZsGreen-3A4-MluI-F: 5′-GAAAACGCGTATGGCTCTCATCCCAGACTTGGCCA-3
Tet-ZsGreen-3A4-NdeI-R: 5′-AGCATATGTCAGGCTCCACTTACGGTGCCATC-3′
The resulting constructs, pLVX-TRE3G-ZsGreen1-CYP3A4 and pLVX-TRE3GZsGreen1-CYP3A5, were confirmed by sequencing. Lentiviruses for pLVX-TRE3GZsGreen1-CYP3A5 or pLVX-TRE3G-ZsGreen1-CYP3A4 and pLVX-EF1a-TRE3G
transactivator were packaged and generated in 293T cells (ATCC), using medium with
10% Tet System Approved FBS (Takara Bio, Mountain View, CA; cat. no. 631101).
AsPC-1 cells were transduced with lentiviral pLVX-TRE3G-ZsGreen1-CYP3A5 or
pLVX-TRE3G-ZsGreen1-CYP3A4 and pLVX-EF1a-TRE3G transactivator. Treatment
with 100 ng/mL doxycycline for 16 hours was sufficient to induce CYP3A4 or CYP3A5.
Stable cells were selected by using 5 µg/mL puromycin and 1.5 mg/mL G418 for 2
weeks.
Western Blot Analysis
Opti-MEM (250 µL) containing siRNA (3.75 µL of 10 µM) was mixed with 250
µL Opti-MEM containing 3.75 µL Lipofectamine RNAiMAX Transfection Reagent,
incubated at room temperature for 10 min, and placed in a 6-well plate. 1 mL of medium
containing 7.5 × 105 cells was added to each well to make the final siRNA concentration
25 nM. The next day, 1.5 mL of medium was added to each well. After 2 additional days,
cells were trypsinized, pelleted by centrifugation, washed with DPBS, and lysed with 50
µL of RIPA Lysis and Extraction Buffer (Thermo Fisher Scientific) containing Halt
Protease Inhibitor Cocktail (Thermo Fisher Scientific). Samples were incubated on ice for
30 min and centrifuged at 16,000 × g for 10 min at 4°C. Protein in the supernatant was
quantified with the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific), and 100 µg
of protein was loaded into NuPAGE 4%–12% Bis-Tris gels (Thermo Fisher Scientific)
with NuPAGE MES SDS running buffer (Thermo Fisher Scientific). Proteins were
transferred from the gels to nitrocellulose membranes with the iBlot gel-transfer system
(Thermo Fisher Scientific). The membranes were blocked for 1 h with Odyssey Blocking
Buffer (LI-COR Biosciences), probed overnight at 4°C with rabbit anti-CYP3A5
(Abcam, cat. # ab108624, 1:1,000 dilution) and mouse anti-β-actin (Sigma, cat. # A5441,
1:2,000 dilution), washed 3x with TBS containing 0.1% Tween-20 (TBS-T) for 10 min
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each, incubated with 1:10,000 dilutions of secondary antibodies conjugated with infrared
dyes (LI-COR Biosciences, goat anti-rabbit IRDye 680RD and goat anti-mouse IRDye
800CW), and washed 3x with TBS-T as above. An Odyssey infrared imager (LI-COR
Biosciences) was used to visualize the protein bands. At least three independent
experiments were performed, and a representative gel is shown. For quantification, gel
images were imported into Image Studio Lite. Equal size quantification rectangles were
placed around each band to be measured. Measurements were visually inspected to
ensure the total protein band was captured. After quantification of triplicate gels, the
relative intensity of each protein band was then determined by normalizing the intensity
of each protein band to that of actin. The relative intensity of control was set as 1.0.
CRISPR/Cas9-Mediated Deletion of CYP3A5
AsPC-1 cells with full deletion of CYP3A5 were generated using CRISPR/Cas9
technology at the St. Jude Center for Advanced Genome Engineering (CAGE). Briefly,
sgRNAs were designed with at least 2 bp of mismatch to any other site in the human
genome to mitigate the risk of off-target editing. Two sets of sgRNAs were used
sequentially to delete the entire ORF of both alleles (Set 1—g8: 5′UGGCUGAAGACUGCUGUGCA-3′ and g4: 5′- UAAUGUACUGCAUGAGUAGU -3′;
Set 2—g12: 5′- AACAGCAGCACUCAGCUAAA-3′ and g7: 5′AGUUGAAAUCUCUGGUGUUC-3′). To generate the AsPC-1CYP3A5−/− line,
400,000 cells were transiently co-transfected with 100 µmol of each sgRNA (Synthego)
in Set 1, 35 µmol SpCas9 protein (from the St. Jude Protein Production Core), and 200 ng
of pMaxGFP via nucleofection (with a 4D-Nucleofector™ X-unit; Lonza) in a small
cuvette, using solution P3 and program EN-158, in accordance with the manufacturer’s
recommended protocol. Five days post nucleofection, cells were single-cell sorted into
96-well plates by FACS for transfected cells based on pMaxGFP expression. After
sorting, cells were clonally expanded and screened for the desired deletion by PCR-based
assays and confirmed with targeted deep sequencing. Specifically, the deletion was
detected using primers hCYP3A5.Del.F (5′- ACCCTTGGACTCCCCGATAACACTGA3′) and hCYP3A5.Del.R (5′- TCTGATGAGAGCTCAGGAGGAGTTGA-3′). The
nucleofection, cloning, and screening process was repeated with sgRNA Set 2 as
described above, and the deletions were sequence confirmed by targeted deep
sequencing. Additionally, the internal primers hCYP3A5.inner.F (5′AGTCACAATCCCTGTGACCTG -3′) and hCYP3A5.inner.R (5′GAAACCTCAGAACTCCCTCCC-3′) were used to verify the loss of the intervening
sequence (by the absence of the band). CYP3A5 deletion was further verified by Western
blot analysis, qRT-PCR, and functional testing.
LC-MS/MS Detection of Midazolam and 1-Hydroxymidazolam
Cells were plated at a concentration of 10,000 cells per well in 384-well white,
opaque, tissue culture–treated microplates (Corning, cat. no. 8804BC). Overexpression
cell lines were induced with 100 ng/mL doxycycline. Twenty-four hours later, the cells
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were treated with clobetasol, ketoconazole, or DMSO. Both clobetasol and ketoconazole
were tested in a dose-response format, using 16 concentrations in 1:2 dilutions ranging
from 0.0003 µM to 10 µM. Additionally all groups were treated with 5 µM midazolam.
The final DMSO concentration for all wells of the assay plates, including the controls,
was 0.66%. Twenty-four hours after drug treatment, the reaction was quenched by adding
acetonitrile (containing 4 µg/mL warfarin as an internal standard) to the wells in a 2:1
volume ratio. The plates were centrifuged for 20 min at 4,000 × g, and the reaction
supernatants were diluted into an equal volume of dH2O. Reference standards of
midazolam and 1-hydroxymidazolam were also prepared in the same fashion, using
culture medium and concentration ranges of 1.19 × 10−6 µM to 10 µM (for midazolam) or
1.19 × 10−7 µM to 1 µM (for 1-hydroxymidazolam). Samples were then frozen at −20 °C
until analyzed by mass spectrometry.
LC-MS/MS analysis was performed using a SCIEX Triple Quad 6500 triplequadrupole mass spectrometer (SCIEX, Forster City, CA) coupled to an ACQUITY
UPLC system (Waters Corporation, Milford, MA). For each unknown sample and
calibration sample, 10 μL was injected onto an Acquity UPLC HSS C18 2.1 mm × 50
mm column (particle size: 1.8 µm) (Waters Corporation). Chromatographic separation
was performed by gradient elution at a constant flow rate of 1 mL/min for 2 min. The
mobile phase consisted of 0.1% formic acid–water (solvent A) and 0.1% formic acid–
acetonitrile (solvent B). The gradient applied was 0.0 min, 90% A–10% B; 0.3 min, 80%
A–20% B; 1.35 min, 80% A–20% B; 1.65 min, 5% A–95% B; and 1.95 min, 10% A–
90% B. The first 0.5 min of eluate was desalted to waste by an integrated Valco valve.
The remaining eluates were directed to the triple quadrupole mass spectrometer, which
was equipped with an electrospray ionization source. LC-MS/MS was performed in
positive polarity (at 3000 V), and the source temperature was 650 °C. Gas 1 and gas 2
settings for nitrogen were set to 60. The curtain gas and collision gas were also nitrogen
and were set to 20 and 10, respectively. Multiple reaction monitoring transitions were
m/z 326 to m/z 291 for MDZ, m/z 342 to m/z 324 for 1-OH MDZ, and m/z 309 to m/z
163 for the IS (warfarin). The declustering potentials, entrance potential, collision energy,
and collision cell exit potential were as follows: 120 V, 12 V, 35V, and 27 V,
respectively, for MDZ; 70 V, 12 V, 30V, and 40 V for 1-OH MDZ; and 57 V, 12V, 44V,
and 20 V for the IS. Data acquisition was conducted with Analyst 1.6.3 (SCIEX) and the
data processes were operated with MultiQuant 2.1.1 software (SCIEX). The stepwise
protocol for cell-based LC-MS/MS detection of CYP3A4 or CYP3A5 activity in cells is
available in the Protocol Exchange (http://doi.org/ 10.21203/rs.2.16299/v1).
Confluence Imaging
Cells were plated at a concentration of 10,000 cells per well in 384-well, black,
tissue culture–treated, clear-bottom polystyrene microplates (Corning, cat. no. 3712BC).
All samples were processed in parallel with samples used for LC-MS/MS (and using the
same methods) until just before the reaction-quenching stage. Cells were then imaged
using a Lionheart FX Automated Live Cell Imager (BioTek, Winooski, VT). Single
images of each well were acquired using phase-contrast microscopy with a 4× objective.
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An LED intensity of 10 was used, with a 100-millisecond integration time and a camera
gain of 6.8. The laser was set to autofocus, and the wells were scanned at a distance of
600 µm in increments of 50 µm with a 0-µm well offset. The vibration CV threshold was
set to 0.01. The instrument was set to add a 30-millisecond delay after plate movement.
Lionheart FX software version 3.05.11 was used to obtain the cell confluence and export
the well-by-well results. Confluence data were normalized in GraphPad Prism 8.2.0,
using the average of six replicates of 0.66% DMSO (set to 100% confluence) for each
cell line. Nonlinear regression curves were fitted using the “log(inhibitor) vs. response
(three parameters)” equation applied to normalized data and were plotted to show
normalized cell confluence over the tested concentration ranges.
Ligand Docking and Molecular Dynamics Simulations
Published crystal structures of ritonavir-bound CYP3A4 (PDB: 3NXU, Chain A)
or CYP3A5 (PDB: 5VEU, Chain A) were loaded into Maestro software (Schrödinger
Release 2019-3). To prepare the protein for docking and simulations, the protein
preparation wizard was used to assign bond orders, add hydrogens, create zero-order
bonds to metals, create disulfide bonds, and fill in missing side chains and loops. Default
parameters were used for the optimization of hydrogen-bond assignment (sampling of
water orientations and use of pH 7.0). Waters beyond 5 Å of het groups or with fewer
than three hydrogen bonds to non-waters were removed. Restrained energy minimization
was applied using the OPLS3e216 forcefield. Prepared protein systems were further
checked by Ramachandran plots, ensuring there were no steric clashes. To generate
receptor grids, ritonavir was selected as the grid-defining ligand for both the CYP3A4
and CYP3A5 systems. Default Van der Waals radius scaling parameters were used
(scaling factor of 1, partial charge cutoff of 0.25).
For docking clobetasol into CYP3A4 and CYP3A5, the 3D structure of clobetasol
was first obtained from the PubChem database (www.pubchem.ncbi.nlm.nih.gov). The
virtual screening workflow panel was used to prepare clobetasol (by generating possible
states at pH 7.0 ± 2.0 and retaining the specified stereochemical properties) and dock it
into CYP3A4 and CYP3A5 in parallel. The most stringent docking mode (extra
precision, “XP”) of Glide217 was used, with the following parameters: dock flexibly,
perform post-docking minimization, and keep 100% of scoring compounds. Of note, only
one pose of clobetasol was returned for each system. For molecular dynamics
simulations, systems were built for clobetasol-docked CYP3A4 and CYP3A5 by using
the system builder panel of Desmond (Schrödinger Release 2019-3). The SPC solvent
model was used, and the forcefield was set to OPLS3e. Solvated systems were loaded
into the workspace by using the molecular dynamics panel. The total simulation time for
each system was set to 200 nanoseconds, with 200-picosecond trajectory recording
intervals. The system energy was set to 1.2, and the ensemble class used was NPT.
Simulations were set to run at 300.0 K and at 1.01325 bar. The option to relax model
systems before simulations was selected.
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Cloning of CYP3A4 and CYP3A5 for Bacterial Protein Expression
The cloning procedure closely followed that previously described115,117. Cloning
was performed in pCW ori+ plasmids harboring either CYP2C8 or CYP2C9 from
Addgene: CYP2C8 and CYP2C9 in pCW ori+ were gifts from Joyce Goldstein (Addgene
plasmid # 69604; http://n2t.net/addgene:69604; RRID:Addgene_69604 and plasmid #
69554; http://n2t.net/addgene:69554; RRID:Addgene_69554). The pCW3A4His plasmid
was generated by replacing the CYP2C8 sequence of the pCW ori+-CYP2C8 plasmid
with a codon-optimized CYP3A4 coding sequence at the NdeI/XbaI sites by GenScript
(Piscataway, NJ), which expresses an N-terminal truncated version of CYP3A4 (with
amino acids 3–24 truncated) with the His-4 tag at the C-terminal as previously
described115. The pCW3A5His expression plasmid was generated by PCR from a cDNA
template coding for full-length CYP3A5 (OriGene, Rockville, MD) by using the forward
and reverse primers 5′ggattcGGCATATGGACTATCTATATGGGACCCGTACACATGGAC-3’ and 5′cggaattccgAAGCTTTTAGTGGTGGTGGTGTCCATCTCTTGAATCCACCTTTAGAA
C-3′ (Invitrogen, Carlsbad, CA). The underlined letters in the primers indicate engineered
restriction sites (NdeI/HindIII). The bold letters indicate engineered ATG start and stop
codons. The PCR reaction was accomplished using a ProFlex PCR system (Life
Technologies, Carlsbad, CA) and Fusion High-Fidelity Master Mix (New England
Biolabs, Ipswitch, MA). The amplification conditions were 95 °C for 2 min followed by
30 cycles of 95 °C for 30 s, 60 °C for 30 s, and 68 °C for 5 min, with a final
polymerization step of 68 °C for 5 min. The PCR product was then digested using
NdeI/HindIII and inserted into the restriction sites in a pCW ori+ plasmid (previously
digested with the corresponding enzymes to remove CYP2C9) by using a Quick Ligation
Kit (New England Biolabs). The resulting pCW3A5His construct encoded an N-terminal
3–24 trans-membrane helix amino acid deletion and a C-terminal 498–501 amino acid
deletion. The C-terminal deletion in CYP3A5 produces a more soluble protein, as
observed previously117. In addition, a His-4 tag to aid nickel affinity chromatography was
engineered at the C-terminal. No other mutations were made in the enzymes. All
constructs were confirmed by DNA sequencing.
Expression and Purification of CYP3A4 and CYP3A5
The expression and purification methods closely followed those previous
described, albeit with a few modifications115,117. The cloned pCW3A4His and
pCW3A5His constructs were co-transformed with a pGro7 plasmid (Takara Bio, Japan)
harboring the E. coli chaperone proteins groES and groEL (henceforth, groESL) into E.
coli DH5-α cells, and transformed cells were co-selected using ampicillin and
chloramphenicol (Gold Biotechnology, Olivette, MO). The chaperone proteins were cotransformed to aid solubility and improve protein yield. Expression of the individual
(CYP3A4 or CYP3A5) gene constructs was achieved by using an isopropyl β-Dthiogalactopyranoside (IPTG) (Gold Biotechnology)–inducible tac promoter system in
the pCW ori+ plasmid.
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Protein production was typically done in 12-L cultures of Terrific Broth (TB)
growth medium (Fisher Scientific, Hampton, NH) distributed between six 4-L conical
flasks. Each flask contained 2000 mL of growth medium supplemented with ampicillin
(50 µg/mL) and chloramphenicol (35 µg/mL). The medium was then inoculated with 20
mL of transformant cells from an overnight culture in the same medium and under the
same conditions. The cells were then grown at 37 °C with 200 rpm agitation to an
exponential phase with an OD600 of 0.5, then the temperature was dropped to 28 °C and
the agitation to 170 rpm. At an OD600 of 0.7–0.8, IPTG (1 mM) and delta-aminolevulinic
acid (1 mM) (Gold Biotechnology) were added to induce P450 production and to
promote heme synthesis, respectively. Approximately 3 g/L of L-(+)-arabinose (SigmaAldrich, St. Louis, MO) was also added to induce expression of the E. coli chaperone
proteins groESL. The transformant cells were grown for a further 48–50 h, then the cells
were harvested by centrifugation at 6000 × g for 10 min at 4 °C by using an F9-6X1000
LEX rotor in a Sorvall Lynx6000 centrifuge (Thermo Fisher Scientific). The supernatant
was discarded, and the cell pellets were resuspended in approximately 500 mL of 0.5 M
potassium phosphate (KPi, pH 7.4) containing 20% glycerol and 1 mM
phenylmethanesulfonyl fluoride (PMSF) protease inhibitor (Sigma-Aldrich). A few
granules of lysozyme (Sigma-Aldrich) were added to facilitate cell lysis. The cells were
lysed by passing them once through a microfluidizer (Microfluidics, Newton, MA);
thereafter, the resulting lysate was supplemented with 10 mM CHAPS and incubated for
2 h (for CYP3A5) or 6 h (for CYP3A4) to release the proteins from the spheroplasts. The
lysates were then centrifuged at 40,000 × g for 60 min at 4 °C and the supernatants were
collected.
Each supernatant was mixed in batch with Ni-NTA resin (Qiagen, Hilden,
Germany) pre-equilibrated with buffer A (0.5 M potassium phosphate, pH 7.4, 1 mM
PMSF, 10 mM CHAPS, 20% glycerol) and incubated overnight at 4 °C with stirring.
Next day, the supernatant–Ni-NTA resin was loaded onto a column and washed with 2
bed volumes (BV) of buffer A. The resin was then washed/buffer exchanged with 10 BV
of buffer B (25 mM potassium phosphate, pH 6.8, 10 mM 2-mercaptoethanol, 20 mM
NaCl, 2% Tween-20, 20% glycerol), followed by another 10 BV of buffer C (buffer B
supplemented with 50 mM MgCl2 and 5 mM ATP) to remove the groESL chaperone
proteins. The resin was next washed with 5 BV of buffer B to remove excess ATP. The
CYPs were then eluted from the resin by using buffer B supplemented with 200 mM
imidazole and were analyzed spectrally (at 250–800 nm) and by SDS-PAGE.
The CYPs were then subjected to a second round of purification using a cation
exchange chromatography column packed with carboxymethyl (CM) sepharose fast-flow
resin (GE Healthcare) pre-equilibrated with buffer B. The column was mounted on an
automated AKTA Avant purification system (GE Healthcare) and eluted via a linear
gradient of NaCl (20–500 mM) with buffer B and buffer B2 (buffer B supplemented with
500 mM NaCl), and each fraction was analyzed by both spectroscopy and SDS-PAGE as
before. Eluted fractions with high A420/A280 (Reinheitszahl, Rz) ratios (≥ 1) were pooled
and concentrated to approximately 3–5 mL by ultrafiltration with a Vivaspin 20
concentrator at 4 °C. The CYPs were then subjected to a final purification step using a
Sephacryl S-200 size-exclusion chromatography column and an AKTA Avant
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purification system with buffer C (100 mM HEPES, pH 7.4, 10 mM 2-mercaptoethanol,
200 mM NaCl, 20% glycerol). Fractions with Rz values of 1.3 or higher were pooled,
concentrated, and stored at −80 °C until use.
UV-Visible Absorbance Titrations with CYP3A4 and CYP3A5
UV–visible experiments were carried out in accordance with previously described
methods218-221. Optical titrations were performed to determine the dissociation constant
(Kd) values for interactions of clobetasol, ketoconazole, and midazolam with CYP3A4 or
CYP3A5. Titrations were performed using 1-cm path-length cuvettes in a SPECTRAmax
PLUS384 UV–Visible spectrophotometer (Molecular Devices, San Jose, CA). Stock
solutions (10 mM) of all compounds were made in DMSO-d6 and titrated (in 1.0 µL
aliquots) in cuvettes containing either ligand-free CYP3A4/CYP3A5 (4–6 µM) or buffer
alone (as a negative control). The total DMSO-d6 concentrations after saturation of
enzyme were kept below 2.2%, and the absorbance spectra of CYP3A4 and CYP3A5
were not affected by DMSO-d6 within this range. Continuous absorbance spectra (250–
800 nm) were recorded at 25 °C. The negative control spectra generated from the buffer
alone were subtracted from the protein absorbance spectra to eliminate the absorbance
due to optical interference from small molecules. In addition, difference spectra were
generated by subtracting the initial ligand-free protein absorbance spectrum from the
ligand-bound spectrum, and the maximum change in absorbance calculated from each
difference spectrum was then plotted against the corresponding ligand concentration.
EPR Spectroscopic Analysis of CYP3A4 and CYP3A5
A continuous-wave X-band EPR spectrum was collected for both CYP3A4 and
CYP3A5. Spectra were obtained at 10 K by using a Bruker ELEXSYS E500 EPR
spectrometer equipped with an ER4122SHQ Super High Q cavity. An Oxford
Instruments ESR900 cryostat connected to an ITC503 was used to control the
temperature. The microwave power was set to 0.5 mW, with the frequency and
modulation amplitude set to 10 GHz and 5 G, respectively. Spectra were collected for
both CYPs in the ligand-free state (200 µM) and with the addition of exogenous
compounds (400 µM).
Statistics for CYP Inhibition
For CYP inhibition, we performed statistical calculations by using one-way
analysis of variance (ANOVA) assuming Gaussian distribution of residuals and equal
standard deviation. Tuckey correction for multiple comparisons was applied. For
CYP3A5 expression in RNA-seq experiments, the edgeR package with Limma and
Voom was first used for linear modeling, empirical Bayes smoothing, and TMM
normalization. Subsequently, all P values were derived from t statistics, then adjusted
with the Benjamini-Hochberg false discovery rate (FDR) adjustment. For protein
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expression we either performed unpaired, two-tailed t tests, assuming Gaussian
distribution and all populations having equal standard deviation, or used a one-way
ANOVA, assuming Gaussian distribution of residuals and equal standard deviation. The
Tuckey method of adjustment for multiple comparisons was applied. Information on
sample size selection is indicated in the figures and corresponding Methods section, and
no data were excluded from the analyses. For all statistical analyses, *** P ≤ 0.0001, **
P ≤ 0.005, * P ≤ 0.05, and ns = not significant (P ≥ 0.05).
COLDSTaR Development and Analysis of Pancreatic Cancer
We find it best to start with data processed uniformly using well-established
methods, such as the UCSC Toil recompute of TCGA data which is available in the form
of Log2(gene counts). We obtained expression data in this form from the TCGA
pancreatic cancer (PAAD) cohort. These counts are back-transformed into a linear scale.
Then, TMM normalization and linear modelling are performed through the edgeR
package211 using limma212 and VOOM213.The output is expression data in units of
Log2(normalized CPM). In the data preparation stage, the sum of expression is calculated
for each gene across all samples. Genes whose sum is zero (completely unexpressed in all
samples) are discarded. In the block-wise computation step, we employ a modified
version of the bigcor package, and calculate the Spearman correlation coefficients and
adjusted p-values (see bigcor function definition in code repository). Pairs of genes with
correlations ≥ 0.6 and adjusted p-values ≤ 0.05 are extracted and saved as final tabular
results. We then use the COLDNet package to calculate and plot a given network
(detailed in code repository). We make all corresponding code available in our GitHub
repository (github.com/wcharleswright).
NetBID Analysis of Pancreatic Cancer
Gene expression was obtained from the same cohort as described in the previous
section, TCGA pancreatic cancer. According to NetBID methods, data were Log2transformed into Log2(FPKM+0.1) and transcripts were filtered by IQR variance,
filtering with a cutoff of 0.3 which resulted in 32,088 transcript sets representing 20,517
genes. The data quality was further assessed by the function draw.eset.QC from the
NetBID2 toolkit183 and 7 outliers were found and removed from subsequent analysis. We
used SJARACNE222 to reconstruct context-dependent signaling networks. The
parameters were configured as follows: p value threshold p=1e-7, data processing
inequality (DPI) tolerance € = 0, and number of bootstraps (NB) = 100. The CYP3A5
subnetwork was extracted and the first neighbors were considered as candidate
transcriptional regulators.
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siRNA Screening of Predicted CYP3A5 Regulators
75 nL of siRNA in Echo Qualified 384-Well Low Dead Volume Microplates
(Labcyte, cat. # LP-0200) was transferred to 384-well clear-bottom plates (Corning, cat. #
3764) with a Labcyte Echo 655T Liquid Handler to yield a final concentration of 25 nM.
5 µL of Opti-MEM I Reduced Serum Medium (Thermo Fisher Scientific, cat. #
31985062) containing 50 nL Lipofectamine RNAiMAX Transfection Reagent (Thermo
Fisher Scientific, cat. # 13778150) was added to each well and incubated for 10 min at
room temperature. 25 µL of medium (RPMI + 10% FBS + 1% glutamax + PenicillinStreptomycin) containing 104 cells was added to each well. The next day, 30 µL of
medium was added to each well. After 2 additional days, plates were imaged with a
Lionheart FX Automated Live Cell Imager (BioTek) as described previously180. Single
images of each well were acquired using phase-contrast microscopy with a 4× objective
and laser autofocus. BioTek Gen5 Image Prime version 3.05.11, was used to obtain the
cell confluence and export the well-by-well results. After imaging, the plates were
processed for Cells-to-CT assay using Cells-to-CT Bulk Lysis Reagents (Thermo Fisher
Scientific, cat. # 4391851C) and Cells-to-CT Bulk Fast Advanced RT Reagents (Thermo
Fisher Scientific, cat. # A39110). The medium was removed from each well, cells were
washed with 50 µL cold DPBS, and the DPBS was removed. Lysis solution (25 µL)
containing 0.25 µL DNase I was added to each well, and plates were shaken for 5 min at
room temperature. Stop solution (2.5 µL) was added to each well, and plates were shaken
for 2 min at room temperature. 5 µL of lysate was transferred to MicroAmp Optical 384Well Reaction Plates (Thermo Fisher Scientific, cat. # 4309849) containing 2x Fast
Advanced RT Buffer (10 µL), 20x Fast Advanced RT Enzyme Mix (1 µL), and nucleasefree H2O (4 µL). Plates were incubated at 37°C for 60 min and 95°C for 5 min. The
resulting cDNA (2 µL) was subjected to multiplexed quantitative polymerase chain
reaction (qPCR) using TaqMan Fast Advanced Master Mix (Thermo Fisher Scientific,
cat. # 4444557) with a 10 µL total reaction volume in an Applied Biosystems 7900HT
system. DNA was denatured at 95°C for 2 min and amplified by 40 cycles of 95°C for 1 s
and 60°C for 20 s. TaqMan gene expression assays specific for CYP3A5
(Hs01070905_m1, FAM-labeled) and GAPDH (Hs03929097_g1, VIC-labeled) were
purchased from Thermo Fisher Scientific. Fold induction values were calculated
according to the 2-ΔΔCT method223, where ΔCT represents the differences in cycle
threshold numbers between the target gene and reference gene and ΔΔCT represents the
relative change in these differences between the control and treatment groups.
qPCR-Based Validation of CYP3A5 Regulators
Opti-MEM (50 µL) containing siRNA (1 µL of 10 µM) was mixed with 50 µL
Opti-MEM containing 1 µL Lipofectamine RNAiMAX Transfection Reagent, incubated
at room temperature for 10 min, and placed in a 24-well plate. 300 µL of medium
containing 1.5 × 105 cells was added to each well to make the final siRNA concentration
25 nM. The next day, 500 µL of medium was added to each well. After 2 additional days,
total RNA was isolated from the cells with Maxwell 16 LEV SimplyRNA Tissue Kits
(Promega), and cDNA was generated from 1 μg of RNA with the SuperScript VILO
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cDNA Synthesis Kit (Invitrogen). The resulting cDNA (2 µL) was subjected to
multiplexed qPCR as above
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CHAPTER 5.

DISCUSSION*

Until now, a CYP3A5 inhibitor that does not also inhibit CYP3A4 has not been
identified. In addition to the difficulty arising from the fact that CYP3A5 and CYP3A4
have a high degree of structural homology, there was a lack of commercially available
tools with which to screen for such a selective inhibitor by using requisite throughput.
Many assays for screening CYP3A4 inhibitors are available with various readouts, such
as luminescence and fluorescence, and are compatible with high-throughput screening224,
but there are no such assays for CYP3A5. We hypothesized that we could exploit the
overlapping substrate specificity of the enzymes and use an assay originally intended for
CYP3A4 to screen for CYP3A5 inhibitors. The luminescence-based assay from Promega
that we used (as detailed in the Methods section) is advertised as having no crossreactivity with CYPs outside the CYP3A family, with the kit being optimized for
CYP3A4. Nevertheless, we hypothesized that, with proper controls and normalization,
the assay would work for CYP3A5. Our hypothesis was validated when we began testing
the assay. Although the higher catalytic activity of CYP3A4 was clear, the properly
controlled assay produced exceptional signal windows that were suitable for parallel
screening and cross-enzyme comparisons. Our screen yielded results showing both zero
CYP3A5 inhibition and total CYP3A5 inhibition. Furthermore, many known inhibitors
were successfully identified from the screen, and a few cross-plate duplicates that served
as internal controls lined up very well and demonstrated assay reproducibility.
Interestingly, our screen also identified a few CYP3A5 enzymatic activators, a
phenomenon already reported in the literature for CYP3A enzymes81,83. Our doseresponse analysis further confirmed the high performance of the assay, as indicated by
the tight replicates and sigmoidal inhibitory curves. After demonstrating the potential of
clobetasol to selectively inhibit CYP3A5 while avoiding CYP3A4, we used a different
assay to test the effect of clobetasol on six other major human CYPs. The IC90
concentration of clobetasol for CYP3A5 (1.8 µM) showed no significant inhibition of
these enzymes. This validated the selectivity of clobetasol not just in the context of
CYP3A4. The lack of CYP3A4 inhibition observed with three different substrates and
two different readouts gave us confidence that clobetasol was potent and selective for
CYP3A5 in cell-free systems.
We identified a cell model that was suited to studying the in vitro effect of
clobetasol by leveraging publicly available RNA-seq data and confirming the results with
in-house sequencing experiments using a panel of cell models that we assembled. We
simultaneously normalized the expression results of the entire TCGA dataset (described
in detail in our stepwise protocol available in the Protocol Exchange164). This benefited
-------------------* Portions of chapter from previously published article; pre-print submission reprinted
with permission of American Chemical Society. Wright, W. C. et al. Clobetasol
Propionate Is a Heme-Mediated Selective Inhibitor of Human Cytochrome P450 3A5. J
Med Chem 63, 1415-1433, https://doi.org/10.1021/acs.jmedchem.9b02067 (2020).180
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our study twofold: 1) it enabled proper and confident interpretation of the results when
comparing CYP3A4 and CYP3A5 expression levels, and 2) it used the same processing
pipeline that we used for our own samples from our cell panel, enabling much more
direct comparisons. Our transcriptomic studies culminated in the understanding that
CYP3A5 was highly expressed in pancreatic cancer but CYP3A4 was not. Notably,
CYP3A4 was predominantly expressed in two cancer types: liver hepatocellular
carcinoma and bile duct cancer, whereas CYP3A5 was highly expressed not only in these
two cancers but also in several others, including PDAC. These findings informed our
decision to procure various pancreatic cancer cell lines. We performed RNA-Seq on each
of these cell lines and clearly demonstrated that CYP3A5 was overexpressed in PDAC.
Moreover, we sought to examine the expression of other CYPs in these models. The CYP
superfamily is broad, with humans expressing 57 CYP enzymes225. We focused on
xenobiotic-metabolizing CYPs because of their relevance to our project, and we showed
that most of them, including CYP3A4, are not expressed in any of these cells. Although it
is entirely plausible that CYPs outside this category are present, they are unlikely to be
expressed at levels as high as those of CYP3A5 or to interfere with our selectivity
studies. There is a dearth of information on CYP3A5 versus CYP3A4 expression in
cancer, but these data helped us to conclude that pancreatic cancer cells were appropriate
models for our cell-based selectivity studies.
We went on to demonstrate the selectivity of clobetasol in vitro by modulating the
expression levels of CYP3A5 or CYP3A4. In WT cells that endogenously express
CYP3A5 but not CYP3A4, we were surprised to see clobetasol behaving as a more
potent inhibitor than ketoconazole, however slightly. Importantly, in CYP3A4-null cells
with a genetic deletion of CYP3A5, the metabolic activity for midazolam was completely
abolished, thus demonstrating that no other enzymes were catalyzing the midazolam
hydroxylation. The midazolam-metabolizing activity was rescued by overexpression of
CYP3A5 but was again abolished by clobetasol, confirming that the effect of clobetasol
was indeed CYP3A5 dependent. Overexpression of CYP3A4 in the CYP3A5-null cells
rescued the midazolam-metabolizing activity but could not be inhibited by clobetasol,
thus confirming that clobetasol inhibits CYP3A5 but not CYP3A4. We were intrigued by
the apparent clobetasol-induced enzymatic activation of CYP3A4 observed at high
concentrations of the compound. Although our Western blot analysis indicated that
clobetasol did not increase the protein levels of CYP3A4, we cannot exclude the
possibility that there is an endogenous CYP3A4 inhibitor present in our cell system that
was somehow replaced by clobetasol. This intriguing phenomenon warrants further
investigation. We also noticed that ketoconazole increased CYP3A4 protein levels, as
reported previously226, but that this increase in protein levels did not hinder our ability to
enzymatically inactivate CYP3A4. Additionally, the relative CYP3A4-specific
contribution to midazolam catalysis was drastically lower than that of CYP3A5 in
DMSO-treated samples, which appears to be consistent with the lower protein levels of
CYP3A4, as compared to CYP3A5, in DMSO-treated samples.
In silico approaches have been used to study differential ligand interactions with
CYP3A4 and CYP3A5. These reports use techniques such as ligand docking and
molecular dynamics simulations to understand the differential behavior of ligands with
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the two homologs, usually focusing on heme–ligand interactions95,227,228. We applied the
same approaches to investigate how clobetasol selectively inhibited CYP3A5 but not its
nearly identical homolog CYP3A4. Clobetasol formed a tight heme–ligand interaction
throughout the simulation for CYP3A5 but preferred a site further from the heme in the
CYP3A4 simulation. To our surprise, the simulations revealed that solvent enters the
binding pocket and becomes stabilized on the heme only in CYP3A4, which is indicative
of the resting (non-inhibited) enzyme state53,172,173. Conversely, clobetasol blocked
solvent access throughout the simulation for CYP3A5, coordinating with the anchoring
cysteine residue through the heme iron. We determined that the subtle differences in the
shape of the active sites of the two enzymes were sufficient to cause discrete binding
orientations for clobetasol, and this ultimately helped us to propose a mechanism for the
selective inhibition. Furthermore, the MD simulations may be consistent with the
enzymatic CYP3A4 activation that we observed at high concentrations of clobetasol. It is
possible that clobetasol stabilizes CYP3A4 in an orientation that allows solvent (and,
therefore, substrate) access to the heme more frequently, but this is of no significant
consequence as only high concentrations produced this effect (and no concentration
produced CYP3A4 inhibition).
We proceeded to experimentally test the model predicted by our MD simulations
by using classical biophysical techniques for studying CYPs, namely UV–visible and
EPR spectroscopy to interrogate the spin states and the overall electronic environment of
the ferric heme iron in both CYPs, using recombinantly expressed proteins. With
CYP3A5, UV–visible titrations distinctly showed a typical type I ligand-binding mode
(indicating the displacement of the axial water ligand) for clobetasol, resulting in the
formation of a five-coordinate ferric heme iron, whereas a type II spectrum shift was
produced for ketoconazole, indicating the replacement of the axial water ligand with the
nitrogen atom from the imidazole moiety of the azole compound to retain the sixcoordinate ferric heme iron state. Both phenomena are consistent with the results of
previous studies on human and bacterial CYPs113,117,229,230. To our surprise, clobetasol
also showed a profoundly higher binding affinity for CYP3A5 when compared to
ketoconazole, the pan-CYP3A inhibitor. In contrast, UV–visible titrations could not
detect a significant spectral shift by which to assign a binding mode for clobetasol in
CYP3A4, although minor spectral perturbations were observed with higher clobetasol
concentrations. Moreover, the spectral binding data generated showed clobetasol to have
a significantly weaker affinity for CYP3A4 when compared to ketoconazole. However,
ketoconazole also produced a type II binding mode in CYP3A4, with binding affinities
similar to those noted with CYP3A5. These findings support the prediction from the MD
simulations that clobetasol occupies a site closer to the heme in CYP3A5 compared to
that in CYP3A4. We further validated this heme-dependent selectivity by using EPR to
monitor the effect of clobetasol on the ferric heme iron in the resting state of both
enzymes. Interestingly, clobetasol induced an LS to an HS ferric heme iron spin state in
only CYP3A5, maintaining an LS ferric heme iron spin state similar to the ligand-free
water-ligated resting form of the protein in CYP3A4. In addition, as expected, midazolam
and ketoconazole induced HS and LS spin states corresponding to typical type I and type
II ligand-bound CYP species in both enzymes. A small proportion of HS was seen in the
ligand-free form of CYP3A4 corresponding to a small portion of the enzyme existing
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without the axial water ligand to keep it in a complete LS spin state. However, this
ligand-free HS does not correspond to a typical HS produced in the presence of a true
type I ligand-bound form that usually presents concurrently with a significant size
reduction in the gz and gy signals as noticed in the midazolam-bound forms of both CYPs
. This feature was also observed in other CYPs from bacteria231,232. Our data confirm
beyond reasonable doubt that the selective type I binding mode induced by clobetasol in
the heme of CYP3A5, but not in that of CYP3A4, represents a true CYP3A5-inhibitor
complex. Indeed, inhibitors that mimic substrates with a type I binding mode are not
novel in the CYP field. Previous studies have shown that bromocryptine displays similar
atypical type I–like binding features in CYP3A4 but is arguably classified as an inhibitor
for the enzyme233,234.In addition, previous studies on bacterial CYPs involving
CYP126A1 in Mycobacterium tuberculosis also identified potent inhibitors that displayed
similar type I–like features218. Our proposed mechanism is that clobetasol initially
presents as a substrate on approaching the heme in CYP3A5, but the enzyme fails to
oxidize the compound, leading to the formation of a pseudosubstrate–CYP complex that
in turn inhibits the enzyme.
Identifying a CYP3A5-selective inhibitor has been challenging for many reasons,
not least of which is the 83% sequence homology between CYP3A4 and CYP3A5235. The
potential applications for such a compound range from delineating substrates of CYP3A4
to studying the role of CYP3A5 as a mediator of drug resistance9 or its involvement in
oncogenic signaling236. We have identified and characterized clobetasol as being capable
of potently and selectively inhibiting CYP3A5. Our work lays the foundation for
developing CYP3A5-selective inhibitors and can be expanded in various ways to uncover
the roles of CYP3A5 both in catalytic mechanisms and in disease-relevant contexts.
In addition to selectively targeting CYP3A5 with chemical-mediated inhibition,
we also sought to target it upstream by elucidating its transcriptional regulators. The
prospect of doing so was challenging since transcriptional regulation of CYP3A5 in
extra-hepatic contexts is poorly understood. To this end, we developed a new
computational pipeline designed to quickly and efficiently calculate co-expression data
from which candidate transcriptional regulators of a given target can be identified. Our
resulting tool, COLDSTaR, overcomes a handful of limitations present in existing
pipelines. Namely, overcoming the need for inference, calculating all-by-all correlation
matrices, computing p-values and adjusting them in one step, and quickly constructing a
co-expression network. COLDSTaR automates all steps of computation including data
normalization and produces an easy to interpret list of gene pairs, their correlation
coefficients, and corresponding adjusted p-values. To generate the very large correlation
matrices necessary for these calculations, we expanded upon research into block-wise
computing. We took advantage of what is known in this area and modified it to fit our
specific needs of all-by-all Spearman-based pairwise calculations. This allowed for
completion of large datasets (hundreds of samples, tens of thousands of genes) to be
analyzed in a matter of an hour, compared to about 1 week if the block-wise technique
were not used. One of the final steps in our workflow is the application of correlation and
statistical thresholds. Applying such thresholds in an application intended to predict
transcriptional regulators is a double-edged sword. Setting the cutoff too high can
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severely limit the number of candidates to work with. Assuming that an expression-based
regulator-target relationship is more subtle than two co-regulated genes, it becomes
desirable to have many candidates as opposed to few. One must also consider the other
possible interpretations of co-expressed genes (Figure 3-2a). Conversely, setting the
cutoff too low may result in overwhelming amounts of candidates, especially in the case
of transcription factors controlling very large subsets of genes (potentially including other
transcription factors). The lower the cutoff, the more threshold-passing correlations are
detected (Figure 3-2c). One further theoretical limitation is the p-value cutoff. While we
take the route of applying the most stringent p-value adjustment, these metrics are based
on random chance assumptions, - not grounded in solid biological context. For example,
p-values < 0.05 certainly do not signify a tested hypothesis is biologically important.
Based on empirical testing, we assigned a cutoff of |rho| ≥ 0.6 and adjusted p-value ≤
0.05. This routinely produced networks with known regulator-target relationships, and
the resulting subnetworks were also typically on the order of < 100 genes, compared to
several hundred when testing correlation cutoffs around |rho| ≥ 0.5.
We highlight that one of the most substantial benefits of COLDSTaR is data
browsing. Other tools do not allow researchers to investigate which two genes are most
tightly correlated in a dataset. This is because the only way to know such information is
to calculate the pairwise relationship of every gene by every gene (all-by-all).
COLDSTaR performs this one-time calculation and allows the resulting lists to be sorted.
This could be particularly useful for asking which gene products in a given pathway are
highest on the list (mTOR pathway, for example). We further developed the downstream
complementary tool COLDNet to take this data and subsequently calculate and visualize
co-expression networks. Rather than simply return a plot of all first neighbor genes in the
network relative to a gene of interest, we also keep the inter-network relationships. This
is especially valuable in cases where the amount of candidate regulators exceeds
experimental testing capability and can be used to help narrow down a list. For example,
a given network may indicate that a particular gene is strongly co-expressed with 90% of
the network (in addition to the gene of interest), prioritizing it for validation. Network
construction is done on the fly for each query gene but is nearly instant due to the coexpression results being pre-computed.
Upon completion of COLDSTaR development, we next sought to use it for
analysis of pancreatic cancer data, as this was relevant to CYP3A5. We analyzed a cohort
from TCGA of this cancer type consisting of 183 tumor samples and > 30,000 expressed
genes. Extracting subnetworks of transcriptional regulators with known downstream
targets produced networks that captured at least some of those targets. This was a good
indication that our tool could capture biologically true relationships in a completely
agnostic way, and only using expression data as input. Once the subnetwork for CYP3A5
was extracted, we obtained 72 co-expressed genes. 60 of these were commerciallyavailable. Additionally, we tested two other methods reportedly capable of predicting
transcriptional regulators (NetBID and Spearman correlation only). Each method
predicted unique CYP3A5 regulator candidates. When we screened them by knocking
them down in AsPC-1 cells and measuring CYP3A5 mRNA, it was evident that
COLDSTaR predictions outperformed the other methods. This wasn’t too surprising
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however, because NetBID is designed to uncover driver genes, and the correlation only
method fails to properly normalize data (leading to skewed results). Moreover,
COLDSTaR started with less than half the number of candidates compared to NetBID but
produced more hits in terms of CYP3A5 knockdown; it exclusively found 8 of the top 10
hits. Interestingly, only 2 of the top 10 hits were transcription factors. We validated
screening hits at the qPCR level and deconvoluted the pooled siRNA hits conferring >
50% CYP3A5 knockdown. Our results were striking and indeed show that transcriptional
regulators of CYP3A5 were captured. Of particular interest was that the top 2 hits were a
peptide and an enzyme, neither of which is a nucleic acid-binding protein. These hits also
reduced CYP3A5 at the protein level. If the experiments were started with a transcription
factor siRNA library, these regulators would have been missed. The same is true for
looking into ChIP-seq data; non-DNA-binding proteins are excluded. This underscores
the importance of considering all classes of gene products as potential transcriptional
regulators, and highlights that these can be predicted computationally with COLDSTaR.
We have successfully targeted CYP3A5 at two distinct and important levels,
illuminating details into its function and regulation. We identified the first isoformselective small molecule inhibitor of CYP3A5. This was challenging due to its wildly
promiscuous ligand binding capability, structural overlap with CYP3A4, and lack of
available assays for CYP3A5. Leveraging high-throughput screening led to the
identification of the FDA-approved clobetasol propionate as a truly selective inhibitor.
Moreover, this compound worked as potently and effectively (and sometimes better) in
cells compared to the gold standard nonselective inhibitor ketoconazole – all while
refraining from CYP3A4 inhibition. Based on our biophysical and computational
endeavors, we demonstrated that subtle differences in active site shapes allow clobetasol
to form a tight heme-ligand interaction exclusively in CYP3A5, serving as the basis for
selective inhibition. This lays the foundation for designing molecules in the future that
exploit these minute differences in an effort to try and overcome CYP3A5-mediated
chemoresistance. We also aimed to uncover the regulators upstream of CYP3A5 in
pancreatic cancer. To do this we developed the novel computational tool COLDSTaR
which performed better than other methods and successfully identified a handful of
CYP3A5 transcriptional regulators. These regulators of CYP3A5 mRNA consisted of a
peptide, two enzymes, and a transcription factor. This is the first report of these factors as
transcriptional regulators of CYP3A5, and sheds light on the poorly-understood topic of
extra-hepatic CYP3A5 regulation. Strikingly, these were identified from a predicted list
containing just 60 candidate genes. This comprises < 0.5% of a standard whole-genome
siRNA library and was performed with publicly-available data. It stands to reason that a
major factor in successful prediction came from the heterogenous input data. These
patient data likely added robustness to the prediction, as any correlations surviving across
the heterogenous tumors have a greater propensity of holding true in a given single
model. This presents a deeper understanding of CYP3A5 regulation in cancer, and
highlights targets that could be the subject of future studies into CYP3A5 in disease.
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